k141_2860_2	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	42.5	73	158	231	3.60e-19	79.7
k141_5748_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	48.6	418	417	575	4.17e-123	367
k141_5748_1	SARG|gb|AAK76137.1|ARO:3000024|patA	32.8	344	417	564	1.80e-40	150
k141_5748_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	22.7	383	417	582	1.34e-23	102
k141_5748_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.4	428	417	579	3.39e-22	97.8
k141_5748_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.1	395	417	579	2.72e-20	92.0
k141_5748_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.0	354	417	664	5.67e-17	82.0
k141_5748_1	SARG|gb|AAK76136.1|ARO:3000025|patB	24.4	357	417	588	2.17e-16	80.1
k141_5748_1	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	50.6	83	417	578	5.06e-16	79.0
k141_5748_1	SARG|gi|695842130|ref|WP_032755430.1|	41.7	84	417	603	1.62e-14	74.3
k141_5748_1	SARG|gi|748767925|ref|WP_040019608.1|	40.0	90	417	623	1.66e-14	74.3
k141_34156_1	SARG|gi|494215524|ref|WP_007131565.1|	62.3	252	250	492	2.85e-110	325
k141_34156_1	SARG|gi|924337096|ref|WP_053474708.1|	62.3	252	250	492	8.08e-110	324
k141_34156_1	SARG|gi|499132967|ref|WP_010860999.1|	62.0	250	250	492	2.29e-109	323
k141_34156_1	SARG|gi|1033309939|gb|OAS18676.1|	62.7	252	250	492	4.59e-109	322
k141_34156_1	SARG|gi|944535691|ref|WP_055747198.1|	63.9	252	250	492	6.49e-109	322
k141_34156_1	SARG|gi|1027702639|ref|WP_063637955.1|	61.9	252	250	492	6.49e-109	322
k141_34156_1	SARG|gi|1005577494|ref|WP_061669299.1|	61.9	252	250	492	9.19e-109	321
k141_34156_1	SARG|gi|498488199|ref|WP_010789887.1|	61.9	252	250	492	9.19e-109	321
k141_34156_1	SARG|gi|926250866|ref|WP_053589133.1|	62.0	250	250	492	1.30e-108	321
k141_34156_1	SARG|gi|951389844|ref|WP_057765492.1|	61.9	252	250	492	1.30e-108	321
k141_34156_2	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	40.5	521	512	533	1.96e-107	329
k141_34156_2	SARG|AF353562.gene.p01	37.6	367	512	369	1.31e-63	210
k141_5785_2	SARG|gi|748767925|ref|WP_040019608.1|	27.8	241	250	623	2.06e-22	94.7
k141_5785_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	29.5	227	250	575	2.66e-22	94.4
k141_5785_2	SARG|gi|695842130|ref|WP_032755430.1|	28.5	239	250	603	2.75e-22	94.4
k141_5785_2	SARG|gi|505420018|ref|WP_015607120.1|	28.5	239	250	603	2.75e-22	94.4
k141_5785_2	SARG|gi|817122037|ref|WP_046494699.1|	29.2	240	250	613	2.77e-22	94.4
k141_5785_2	SARG|gi|663350985|ref|WP_030349761.1|	27.6	239	250	613	1.27e-21	92.4
k141_5785_2	SARG|gi|739906046|ref|WP_037756452.1|	29.3	239	250	620	1.73e-21	92.0
k141_5785_2	SARG|gi|953808775|ref|WP_058042812.1|	30.7	218	250	608	2.33e-21	91.7
k141_5785_2	SARG|gi|516574297|ref|WP_017949361.1|	29.3	239	250	620	2.35e-21	91.7
k141_5785_2	SARG|gi|558888514|ref|WP_023543283.1|	28.5	239	250	615	5.83e-21	90.5
k141_5785_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.7	223	227	228	4.76e-52	167
k141_5785_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.3	221	227	219	5.85e-51	164
k141_5785_4	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.6	219	227	219	5.99e-48	156
k141_5785_4	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.6	219	227	220	6.16e-48	156
k141_5785_4	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.6	219	227	220	8.71e-48	155
k141_5785_4	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	219	227	219	4.78e-47	154
k141_5785_4	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.6	219	227	220	6.95e-47	153
k141_5785_4	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.6	228	227	231	1.69e-44	147
k141_5785_4	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	37.8	230	227	252	2.13e-44	148
k141_5785_4	SARG|ZP_02848503	38.8	219	227	221	2.55e-44	147
k141_5785_5	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.4	212	443	365	1.51e-20	91.7
k141_5785_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.3	220	443	370	7.14e-20	89.7
k141_5785_5	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.9	225	443	381	1.94e-19	88.6
k141_5785_5	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.9	225	443	381	1.94e-19	88.6
k141_5785_5	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.6	236	443	381	2.61e-19	88.2
k141_5785_5	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.6	236	443	381	2.61e-19	88.2
k141_5785_5	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.4	225	443	381	3.52e-19	87.8
k141_5785_5	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.4	225	443	381	3.52e-19	87.8
k141_5785_5	CARD|gb|CYF42523.1|ARO:3004047|kdpD	23.6	280	443	885	5.68e-14	73.2
k141_5785_6	CARD|gb|BAA15221.2|ARO:3000263|marA	31.9	94	282	127	4.77e-10	55.5
k141_11500_4	SARG|gb|CAE00499.1|ARO:3003835|cdeA	28.8	423	464	441	2.27e-48	171
k141_11500_4	SARG|gi|488374619|ref|WP_002444004.1|	24.5	432	464	452	6.80e-41	150
k141_11500_4	SARG|HE999704.1.gene3064.p01	34.6	205	464	241	2.46e-35	130
k141_11500_4	SARG|gi|441475675|emb|CCQ25429.1|	39.0	141	464	211	1.64e-26	105
k141_17234_15	SARG|gb|AAK76137.1|ARO:3000024|patA	28.1	203	348	564	4.68e-14	72.0
k141_17234_15	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.2	211	348	664	1.24e-11	64.7
k141_17234_15	SARG|gb|AAK76136.1|ARO:3000025|patB	24.3	210	348	588	2.73e-10	60.5
k141_17234_15	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	24.8	206	348	578	1.07e-07	52.4
k141_17235_3	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	48.7	191	194	703	1.13e-49	169
k141_17287_2	SARG|gi|686392252|ref|WP_031906577.1|	36.3	659	686	668	3.40e-128	393
k141_17287_2	SARG|gi|928780991|ref|WP_053862229.1|	36.3	659	686	668	1.34e-127	392
k141_17287_2	SARG|gi|486697816|ref|WP_001620256.1|	36.1	659	686	668	3.73e-127	390
k141_17287_2	SARG|gi|686322767|ref|WP_031876626.1|	36.1	659	686	668	3.73e-127	390
k141_17287_2	SARG|gi|686316946|ref|WP_031873770.1|	36.1	659	686	668	3.73e-127	390
k141_17287_2	SARG|AAX14397	36.1	659	686	668	5.25e-127	390
k141_17287_2	SARG|CAL22891	36.1	659	686	668	5.25e-127	390
k141_17287_2	SARG|ABQ96639	36.1	659	686	668	5.25e-127	390
k141_17287_2	SARG|gi|727743592|ref|WP_033859381.1|	36.1	659	686	668	5.25e-127	390
k141_17287_2	SARG|gi|686333344|ref|WP_031880881.1|	36.1	659	686	668	5.25e-127	390
k141_23010_50	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	30.4	158	158	341	1.37e-18	79.7
k141_11673_1	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.8	258	276	451	2.90e-34	127
k141_11673_1	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	204	276	381	3.42e-21	90.9
k141_11673_1	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.9	204	276	381	3.42e-21	90.9
k141_11673_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.2	202	276	381	8.79e-21	89.7
k141_11673_1	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.2	202	276	381	8.79e-21	89.7
k141_11673_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.5	204	276	381	4.22e-20	87.8
k141_11673_1	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.5	204	276	381	4.22e-20	87.8
k141_11673_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.5	212	276	370	5.28e-20	87.4
k141_11673_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.4	244	276	365	1.30e-19	86.3
k141_3078_2	SARG|gi|441475675|emb|CCQ25429.1|	37.1	132	318	211	9.71e-18	79.3
k141_3078_2	SARG|HE999704.1.gene3064.p01	37.1	132	318	241	1.65e-17	79.3
k141_42999_2	SARG|gi|953808775|ref|WP_058042812.1|	32.0	231	259	608	7.46e-23	96.3
k141_42999_2	SARG|gi|817122037|ref|WP_046494699.1|	29.3	239	259	613	1.02e-22	95.9
k141_42999_2	SARG|gi|930482089|ref|WP_054228897.1|	31.4	226	259	599	4.59e-22	94.0
k141_42999_2	SARG|gi|985844137|ref|WP_060895163.1|	31.4	226	259	599	4.59e-22	94.0
k141_42999_2	SARG|gb|AAK76137.1|ARO:3000024|patA	27.8	223	259	564	1.49e-21	92.4
k141_42999_2	SARG|gi|663350985|ref|WP_030349761.1|	28.7	247	259	613	1.57e-21	92.4
k141_42999_2	SARG|gi|1033217078|gb|OAR27197.1|	29.3	242	259	601	2.85e-21	91.7
k141_42999_2	SARG|gi|664556405|ref|WP_031071225.1|	30.3	244	259	602	2.85e-21	91.7
k141_42999_2	SARG|gi|860594225|ref|WP_048475168.1|	31.0	216	259	620	2.90e-21	91.7
k141_42999_2	SARG|gi|496018010|ref|WP_008742581.1|	29.5	234	259	623	2.91e-21	91.7
k141_31477_1	SARG|ABV82118	24.4	393	577	639	1.79e-20	94.4
k141_31477_1	SARG|gi|1004359922|gb|AMP42228.1|	26.8	395	577	639	1.79e-20	94.4
k141_31477_1	SARG|ZP_03989103	24.7	393	577	639	2.38e-20	94.0
k141_31477_1	SARG|ABV82120	24.7	393	577	639	2.38e-20	94.0
k141_31477_1	megares|MEG_7171|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	24.2	393	577	639	2.38e-20	94.0
k141_31477_1	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.2	394	577	629	3.09e-20	93.6
k141_31477_1	SARG|AJ295238.gene.p01	24.4	393	577	639	3.15e-20	93.6
k141_31477_1	ResF|tet(O/W)_5_AM889122_1	27.2	394	577	639	3.15e-20	93.6
k141_31477_1	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	393	577	629	5.43e-20	92.8
k141_31477_1	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.2	394	577	629	5.43e-20	92.8
k141_37277_14	SARG|gi|542061059|gb|ERI11611.1|	26.3	243	233	316	9.30e-23	93.2
k141_37277_14	SARG|gi|445996719|ref|WP_000074574.1|	26.0	235	233	309	1.17e-22	92.8
k141_37277_14	SARG|gi|445996710|ref|WP_000074565.1|	25.2	238	233	309	2.25e-22	92.0
k141_37277_14	SARG|gi|445996723|ref|WP_000074578.1|	26.0	235	233	309	3.12e-22	91.7
k141_37277_14	SARG|gi|445996722|ref|WP_000074577.1|	25.5	235	233	309	4.32e-22	91.3
k141_37277_14	SARG|gi|1043490477|ref|WP_065382463.1|	25.5	235	233	309	8.30e-22	90.5
k141_37277_14	SARG|gi|445996726|ref|WP_000074581.1|	25.5	235	233	309	8.30e-22	90.5
k141_37277_14	SARG|gi|507054395|ref|WP_016125339.1|	25.5	235	233	309	8.30e-22	90.5
k141_37277_14	SARG|gi|895808656|emb|COR83787.1|	24.8	238	233	309	8.30e-22	90.5
k141_37277_14	SARG|gi|445996724|ref|WP_000074579.1|	25.1	235	233	309	1.15e-21	90.1
k141_14682_2	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.4	148	158	381	2.79e-20	84.7
k141_14682_2	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.4	148	158	381	2.79e-20	84.7
k141_14682_2	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.9	144	158	381	1.90e-19	82.4
k141_14682_2	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.9	144	158	381	1.90e-19	82.4
k141_14682_2	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.6	144	158	381	4.59e-18	78.6
k141_14682_2	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.6	144	158	381	4.59e-18	78.6
k141_14682_2	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.6	144	158	381	8.65e-18	77.8
k141_14682_2	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.6	144	158	381	8.65e-18	77.8
k141_14682_2	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.9	144	158	381	4.21e-17	75.9
k141_14682_2	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.9	144	158	381	4.21e-17	75.9
k141_11975_1	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	25.5	349	451	397	3.36e-18	85.1
k141_39942_2	SARG|gi|748767925|ref|WP_040019608.1|	37.1	334	401	623	5.75e-62	209
k141_39942_2	SARG|gi|928900436|ref|WP_053931243.1|	36.3	333	401	600	2.81e-61	207
k141_39942_2	SARG|gi|664579989|ref|WP_031094015.1|	36.3	333	401	601	2.87e-61	207
k141_39942_2	SARG|gi|558888514|ref|WP_023543283.1|	36.4	324	401	615	7.13e-61	206
k141_39942_2	SARG|gi|943909899|ref|WP_055545300.1|	36.9	325	401	601	1.51e-60	205
k141_39942_2	SARG|gi|517347347|ref|WP_018522839.1|	36.9	333	401	601	1.51e-60	205
k141_39942_2	SARG|gi|639148059|ref|WP_024490169.1|	33.9	392	401	602	1.54e-60	205
k141_39942_2	SARG|gi|943896259|ref|WP_055534530.1|	36.5	326	401	601	2.94e-60	204
k141_39942_2	SARG|AF170880.4.gene1.p01	36.1	324	401	615	5.22e-60	204
k141_39942_2	SARG|gi|516795764|ref|WP_018105258.1|	36.7	324	401	601	2.15e-59	202
k141_6181_1	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	31.5	130	136	700	3.67e-12	61.2
k141_6181_1	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	30.8	130	136	700	1.26e-11	59.7
k141_6181_1	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.0	130	136	700	8.07e-11	57.4
k141_6181_1	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.8	130	136	706	8.07e-11	57.4
k141_3238_1	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	41.5	118	125	126	1.64e-29	102
k141_20103_11	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	38.3	81	91	323	1.24e-12	60.5
k141_20103_11	SARG|gi|552942232|ref|WP_023043160.1|	39.5	81	91	323	1.70e-12	60.1
k141_20103_11	SARG|AY082011.1.gene6.p01	39.5	81	91	323	1.70e-12	60.1
k141_20103_11	SARG|gi|737310392|ref|WP_035293250.1|	42.0	81	91	323	1.14e-11	57.8
k141_20103_11	SARG|DQ018711.1.gene4.p01	42.0	81	91	322	1.56e-11	57.4
k141_20103_11	SARG|gi|746609237|ref|WP_039635344.1|	40.7	81	91	322	1.42e-10	54.7
k141_20103_11	SARG|AF155139.2.gene6.p01	42.0	81	91	322	1.42e-10	54.7
k141_20103_11	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	39.5	81	91	337	1.98e-10	54.3
k141_20103_11	SARG|KF478993.1.gene2.p01	37.0	81	91	350	5.14e-10	53.1
k141_20103_11	SARG|gi|738848198|ref|WP_036737307.1|	40.7	81	91	323	6.85e-10	52.8
k141_8877_4	SARG|gb|AAC74000.1|ARO:3003950|msbA	24.5	485	569	582	7.00e-35	137
k141_8877_4	SARG|gi|860594225|ref|WP_048475168.1|	38.5	226	569	620	1.86e-33	134
k141_8877_4	SARG|gi|748767925|ref|WP_040019608.1|	37.0	227	569	623	8.39e-33	132
k141_8877_4	SARG|gi|764446018|ref|WP_044369325.1|	37.3	225	569	605	2.46e-32	130
k141_8877_4	SARG|gi|1045390184|ref|WP_065479071.1|	37.5	224	569	605	2.46e-32	130
k141_8877_4	SARG|gi|917229923|ref|WP_051836635.1|	38.1	226	569	620	2.70e-32	130
k141_8877_4	SARG|gi|930482089|ref|WP_054228897.1|	35.2	236	569	599	3.19e-32	130
k141_8877_4	SARG|gi|985844137|ref|WP_060895163.1|	35.2	236	569	599	3.19e-32	130
k141_8877_4	SARG|gi|948137056|ref|WP_056795395.1|	36.9	225	569	602	3.25e-32	130
k141_8877_4	SARG|gi|695887424|ref|WP_032788534.1|	37.3	225	569	605	4.46e-32	129
k141_503_7	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.2	462	531	654	1.46e-33	134
k141_503_7	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.2	462	531	670	1.58e-33	134
k141_503_7	SARG|AAB51122	26.2	462	531	670	1.58e-33	134
k141_503_7	SARG|Q08425	26.2	462	531	641	2.49e-33	133
k141_503_7	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.2	462	531	657	2.70e-33	133
k141_503_7	SARG|Z21523.gene.p01	26.2	462	531	657	2.70e-33	133
k141_503_7	SARG|Q52360	26.8	456	531	641	1.11e-32	131
k141_503_7	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.9	467	531	641	1.11e-32	131
k141_503_7	SARG|AAZ79478	25.9	467	531	657	1.19e-32	131
k141_503_7	SARG|P70882	26.5	456	531	641	2.70e-32	130
k141_504_2	SARG|DQ018711.1.gene4.p01	33.3	225	263	322	7.87e-24	97.1
k141_504_2	SARG|gi|737310392|ref|WP_035293250.1|	33.3	225	263	323	7.98e-24	97.1
k141_504_2	SARG|gi|746609237|ref|WP_039635344.1|	32.9	225	263	322	4.00e-23	95.1
k141_504_2	SARG|AF155139.2.gene6.p01	34.1	220	263	322	5.33e-22	92.0
k141_12076_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	31.6	320	372	885	2.50e-48	174
k141_12076_1	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.1	217	372	361	4.28e-15	74.7
k141_12076_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.0	225	235	225	2.41e-64	198
k141_12076_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.0	225	235	225	2.41e-64	198
k141_12076_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.4	228	235	231	6.19e-47	154
k141_12076_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	35.4	223	235	230	5.36e-45	149
k141_12076_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	33.3	222	235	229	2.93e-44	147
k141_12076_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.0	226	235	232	6.34e-44	146
k141_12076_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.0	226	235	232	6.34e-44	146
k141_12076_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.7	223	235	231	4.88e-43	144
k141_12076_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.7	223	235	231	1.94e-42	142
k141_12076_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.7	223	235	231	2.73e-42	142
k141_663_1	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	30.8	321	467	641	7.55e-34	133
k141_663_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	48.6	253	256	255	4.24e-85	253
k141_663_2	SARG|gi|736472622|ref|WP_034494292.1|	40.5	220	256	648	5.72e-55	186
k141_663_2	SARG|gi|1035670474|ref|WP_064517458.1|	40.0	220	256	648	2.98e-54	184
k141_663_2	SARG|gi|502669352|ref|WP_012905216.1|	40.5	220	256	648	2.98e-54	184
k141_663_2	SARG|gi|1035717981|ref|WP_064557480.1|	40.0	220	256	648	2.98e-54	184
k141_663_2	SARG|gi|823326845|ref|WP_047080664.1|	39.1	220	256	648	4.14e-54	183
k141_663_2	SARG|gi|754724054|ref|WP_042095806.1|	38.2	241	256	648	5.76e-54	183
k141_663_2	SARG|gi|740856590|ref|WP_038641842.1|	40.5	220	256	648	5.76e-54	183
k141_663_2	SARG|gi|693238509|ref|WP_032348033.1|	38.2	241	256	648	5.76e-54	183
k141_663_2	SARG|gi|485870849|ref|WP_001467831.1|	38.2	241	256	648	5.76e-54	183
k141_14846_5	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.4	222	242	368	4.28e-23	95.1
k141_14846_5	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.4	222	242	367	5.84e-23	94.7
k141_14846_5	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.0	225	242	381	3.32e-22	92.8
k141_14846_5	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.0	225	242	381	3.32e-22	92.8
k141_14846_5	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.7	225	242	381	6.27e-22	92.0
k141_14846_5	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.7	225	242	381	6.27e-22	92.0
k141_14846_5	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.2	248	242	384	2.30e-21	90.5
k141_14846_5	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	28.2	248	242	384	2.30e-21	90.5
k141_14846_5	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	29.1	223	242	386	3.20e-21	90.1
k141_14846_5	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	29.1	223	242	386	3.20e-21	90.1
k141_683_2	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	23.8	606	572	633	3.49e-34	136
k141_43263_5	ResF|penA_1_AF515059_1	24.6	329	955	581	8.35e-06	48.5
k141_37378_5	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.5	310	321	343	1.03e-53	178
k141_37378_5	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	30.1	309	321	325	4.17e-47	160
k141_37378_5	SARG|gb|AAA26793|ARO:3003748|oleC	30.3	307	321	325	8.22e-47	159
k141_37378_5	SARG|gi|542061059|gb|ERI11611.1|	37.3	225	321	316	6.66e-42	146
k141_37378_5	SARG|YP_001373621	35.5	228	321	318	5.90e-39	139
k141_37378_5	SARG|P42332	31.2	308	321	306	6.62e-38	135
k141_37378_5	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	31.2	308	321	306	6.62e-38	135
k141_37378_5	SARG|gi|510143239|gb|AGN36970.1|	31.2	308	321	313	7.75e-38	135
k141_37378_5	SARG|ABB80128	31.0	310	321	306	9.27e-38	135
k141_37378_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.0	310	321	307	2.60e-37	134
k141_37378_7	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.1	207	207	204	1.00e-21	87.4
k141_37378_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.4	102	207	228	2.06e-08	51.6
k141_9016_4	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	22.3	328	393	370	4.34e-08	53.5
k141_9016_4	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.3	284	393	361	1.32e-07	52.0
k141_9016_4	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.1	216	393	365	9.82e-07	49.3
k141_9016_4	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	202	393	381	7.41e-06	46.6
k141_9016_4	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	202	393	381	7.41e-06	46.6
k141_9016_5	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.3	226	225	232	2.90e-45	149
k141_9016_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.3	223	225	231	7.07e-43	143
k141_9016_5	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.9	223	225	228	9.19e-43	143
k141_9016_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.4	218	225	219	1.79e-40	137
k141_9016_5	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.3	233	225	233	2.61e-40	137
k141_9016_5	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.3	232	225	235	1.54e-39	135
k141_9016_5	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.5	234	225	231	7.71e-39	133
k141_9016_5	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	33.8	234	225	232	1.12e-38	132
k141_9016_5	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	34.6	234	225	232	1.57e-38	132
k141_9016_5	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.5	231	225	231	2.16e-38	132
k141_12174_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	32.9	146	175	307	1.70e-22	90.5
k141_12174_1	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.3	152	175	293	3.84e-20	84.0
k141_12174_1	SARG|gi|507035724|ref|WP_016107411.1|	37.6	117	175	309	1.22e-18	80.1
k141_12174_1	SARG|gi|445996698|ref|WP_000074553.1|	37.6	117	175	309	1.22e-18	80.1
k141_12174_1	SARG|gi|542061059|gb|ERI11611.1|	36.6	112	175	316	1.31e-18	80.1
k141_12174_1	SARG|gi|488120365|ref|WP_002191762.1|	37.6	117	175	309	1.68e-18	79.7
k141_12174_1	SARG|gi|488042066|ref|WP_002113463.1|	37.6	117	175	309	1.68e-18	79.7
k141_12174_1	SARG|gi|507023808|ref|WP_016095885.1|	37.6	117	175	309	1.68e-18	79.7
k141_12174_1	SARG|gi|488068784|ref|WP_002140181.1|	37.6	117	175	309	1.68e-18	79.7
k141_12174_1	SARG|gi|447057510|ref|WP_001134766.1|	37.6	117	175	309	1.68e-18	79.7
k141_37409_14	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	45.7	680	646	703	9.95e-179	523
k141_37409_21	SARG|gi|835330218|ref|WP_047457825.1|	39.2	222	347	648	4.67e-39	145
k141_37409_21	SARG|YP_001453760	39.2	222	347	648	4.67e-39	145
k141_37409_21	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	31.0	213	347	343	1.22e-25	104
k141_37409_21	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.6	227	347	307	3.09e-23	97.1
k141_37409_21	SARG|gb|AAA26793|ARO:3003748|oleC	29.1	213	347	325	2.71e-22	94.7
k141_37409_21	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	29.1	213	347	325	2.71e-22	94.7
k141_37409_21	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	27.8	281	347	293	1.17e-18	84.0
k141_37409_21	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.3	230	347	351	5.60e-10	58.9
k141_37409_21	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	28.7	115	347	351	1.78e-09	57.4
k141_837_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	47.0	526	599	575	2.72e-152	449
k141_837_1	SARG|gb|AAK76137.1|ARO:3000024|patA	36.8	525	599	564	4.62e-106	330
k141_837_1	SARG|gb|AAK76136.1|ARO:3000025|patB	31.0	526	599	588	4.55e-56	198
k141_837_1	SARG|gi|930482089|ref|WP_054228897.1|	34.9	344	599	599	1.45e-55	197
k141_837_1	SARG|gi|985844137|ref|WP_060895163.1|	34.9	344	599	599	1.45e-55	197
k141_837_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.0	585	599	664	7.53e-55	196
k141_837_1	SARG|gi|943938624|ref|WP_055567802.1|	33.8	361	599	602	1.05e-54	194
k141_837_1	SARG|gi|748767925|ref|WP_040019608.1|	33.1	360	599	623	3.86e-54	193
k141_837_1	SARG|gi|943909899|ref|WP_055545300.1|	33.3	360	599	601	5.18e-54	192
k141_837_1	SARG|gi|501350226|ref|WP_012381861.1|	34.7	337	599	603	5.35e-54	192
k141_837_2	SARG|gb|AAK76136.1|ARO:3000025|patB	36.8	584	608	588	1.19e-126	384
k141_837_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	51.7	327	608	362	9.10e-112	338
k141_837_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.9	515	608	664	1.07e-110	345
k141_837_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	34.9	591	608	579	1.57e-94	300
k141_837_2	SARG|AF170880.4.gene1.p01	32.6	552	608	615	6.33e-92	295
k141_837_2	SARG|gi|496018010|ref|WP_008742581.1|	34.7	521	608	623	1.52e-91	294
k141_837_2	SARG|gi|948137056|ref|WP_056795395.1|	34.1	522	608	602	2.48e-91	293
k141_837_2	SARG|gi|917166849|ref|WP_051773561.1|	34.8	523	608	620	2.77e-91	293
k141_837_2	SARG|gi|558888514|ref|WP_023543283.1|	32.4	552	608	615	3.43e-91	293
k141_837_2	SARG|gi|497748188|ref|WP_010062372.1|	33.4	521	608	605	3.75e-91	292
k141_29152_1	SARG|gb|AAV85982.1|ARO:3000535|macB	24.3	477	473	644	4.97e-18	85.9
k141_29152_1	SARG|gi|693066875|ref|WP_032232318.1|	30.6	147	473	648	2.08e-11	65.1
k141_29152_1	SARG|gi|502669352|ref|WP_012905216.1|	28.9	149	473	648	4.82e-11	63.9
k141_29152_1	SARG|gi|485866062|ref|WP_001464282.1|	29.9	147	473	648	6.37e-11	63.5
k141_29152_1	SARG|gi|486129995|ref|WP_001513696.1|	22.3	479	473	648	6.37e-11	63.5
k141_29152_1	SARG|gi|487410704|ref|WP_001678420.1|	29.9	147	473	648	6.37e-11	63.5
k141_29152_1	SARG|gi|835330218|ref|WP_047457825.1|	29.3	147	473	648	8.43e-11	63.2
k141_29152_1	SARG|YP_001453760	29.3	147	473	648	8.43e-11	63.2
k141_29152_1	SARG|gi|921980855|ref|WP_053272142.1|	22.3	479	473	648	8.43e-11	63.2
k141_29152_1	SARG|gi|671541568|ref|WP_031525212.1|	29.3	147	473	648	8.43e-11	63.2
k141_29152_3	SARG|gi|585349466|ref|WP_024231081.1|	45.1	224	244	648	3.55e-59	196
k141_29152_3	SARG|gi|585345156|ref|WP_024226778.1|	45.1	224	244	648	3.55e-59	196
k141_29152_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	39.1	235	244	255	8.88e-58	183
k141_29152_3	SARG|gi|803568669|ref|WP_046077412.1|	44.8	223	244	648	3.71e-57	191
k141_29152_3	SARG|gi|446110352|ref|WP_000188207.1|	44.8	223	244	648	3.71e-57	191
k141_29152_3	SARG|YP_002382193	44.8	223	244	648	3.71e-57	191
k141_29152_3	SARG|gi|803575554|ref|WP_046081557.1|	44.8	223	244	648	3.71e-57	191
k141_29152_3	SARG|gi|446110351|ref|WP_000188206.1|	44.8	223	244	648	3.71e-57	191
k141_29152_3	SARG|gi|494938585|ref|WP_007664615.1|	44.4	223	244	647	7.29e-55	185
k141_29152_3	SARG|gb|AAV85982.1|ARO:3000535|macB	43.2	220	244	644	1.90e-52	178
k141_29152_7	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.0	243	495	364	1.16e-20	92.4
k141_29152_7	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.0	243	495	364	1.16e-20	92.4
k141_29152_7	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.4	299	495	361	4.98e-20	90.5
k141_29152_7	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	22.1	199	495	359	1.99e-15	76.6
k141_29152_8	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	219	226	220	3.50e-55	174
k141_29152_8	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	219	226	219	4.81e-55	174
k141_29152_8	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.1	219	226	220	4.95e-55	174
k141_29152_8	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.6	219	226	219	3.86e-54	172
k141_29152_8	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	39.6	227	226	230	1.07e-53	171
k141_29152_8	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.7	219	226	220	1.81e-52	167
k141_29152_8	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.4	231	226	232	1.03e-51	166
k141_29152_8	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.5	228	226	232	1.46e-51	166
k141_29152_8	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.5	228	226	232	1.46e-51	166
k141_29152_8	SARG|ZP_02848503	38.5	221	226	221	3.00e-51	164
k141_29152_10	SARG|gi|446110305|ref|WP_000188160.1|	41.8	237	235	648	1.04e-55	187
k141_29152_10	SARG|gi|1035686596|ref|WP_064530178.1|	41.8	237	235	648	2.01e-55	186
k141_29152_10	SARG|gi|974672242|ref|WP_059256507.1|	43.2	222	235	648	3.89e-55	185
k141_29152_10	SARG|gi|974641719|ref|WP_059227752.1|	43.2	222	235	648	3.89e-55	185
k141_29152_10	SARG|Q83LR7	41.4	237	235	648	3.89e-55	185
k141_29152_10	SARG|gi|647325472|ref|WP_025760953.1|	41.4	237	235	648	3.89e-55	185
k141_29152_10	SARG|gi|647323678|ref|WP_025760497.1|	41.4	237	235	648	3.89e-55	185
k141_29152_10	SARG|gi|446110299|ref|WP_000188154.1|	43.2	222	235	648	3.89e-55	185
k141_29152_10	SARG|ZP_02903696	43.2	222	235	648	3.89e-55	185
k141_29152_10	SARG|gi|974688082|ref|WP_059271287.1|	43.2	222	235	648	3.89e-55	185
k141_43342_1	SARG|gi|171851258|emb|CAQ04234.1|	41.1	56	254	483	1.05e-06	48.1
k141_43342_1	SARG|gi|736993687|ref|WP_034989673.1|	39.3	56	254	513	6.13e-06	45.8
k141_43342_1	SARG|AF024666.2.gene6.p01	39.3	56	254	513	6.13e-06	45.8
k141_29166_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	46.3	147	139	703	1.24e-34	125
k141_845_1	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	49.1	112	117	225	9.98e-33	113
k141_845_1	CARD|gb|AAC73788.1|ARO:3003841|kdpE	49.1	112	117	225	9.98e-33	113
k141_845_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.5	111	117	229	2.63e-27	99.4
k141_845_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.2	114	117	232	3.38e-25	94.0
k141_845_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.4	111	117	233	2.68e-24	91.7
k141_845_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.5	114	117	231	5.09e-24	90.9
k141_845_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.6	112	117	230	9.87e-24	90.1
k141_845_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.1	110	117	232	4.01e-23	88.6
k141_845_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.1	110	117	232	4.01e-23	88.6
k141_845_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	39.6	111	117	235	4.25e-23	88.6
k141_845_2	CARD|gb|CYF42523.1|ARO:3004047|kdpD	34.9	232	357	885	1.59e-28	115
k141_845_2	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.7	216	357	367	9.48e-15	73.6
k141_845_2	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.7	216	357	368	9.53e-15	73.6
k141_845_2	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.9	222	357	365	2.41e-13	69.3
k141_845_2	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.8	240	357	392	3.64e-13	68.9
k141_845_2	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.4	231	357	370	1.92e-12	66.6
k141_845_2	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.2	246	357	354	5.76e-12	65.1
k141_845_2	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.9	238	357	386	8.77e-12	64.7
k141_845_2	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	26.9	238	357	386	8.77e-12	64.7
k141_845_2	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.1	240	357	354	1.38e-11	63.9
k141_855_3	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.8	266	424	355	3.57e-18	84.3
k141_855_3	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	27.8	266	424	355	3.57e-18	84.3
k141_855_3	SARG|ACM47285	27.8	266	424	363	3.84e-18	84.3
k141_17796_1	SARG|gi|507035724|ref|WP_016107411.1|	26.3	160	169	309	4.94e-06	44.3
k141_17796_1	SARG|gb|MBW0770001.1|ARO:3007026|salB	27.0	148	169	541	5.87e-06	44.3
k141_17796_1	SARG|gi|171851258|emb|CAQ04234.1|	33.8	68	169	483	7.74e-06	43.9
k141_29265_4	SARG|gi|445996732|ref|WP_000074587.1|	35.3	300	294	309	4.21e-49	164
k141_29265_4	SARG|gi|445996719|ref|WP_000074574.1|	40.1	227	294	309	1.18e-48	163
k141_29265_4	SARG|gi|507055561|ref|WP_016126482.1|	39.2	227	294	309	1.65e-48	162
k141_29265_4	SARG|gi|445996710|ref|WP_000074565.1|	40.5	227	294	309	1.65e-48	162
k141_29265_4	SARG|gi|445996698|ref|WP_000074553.1|	35.0	300	294	309	2.33e-48	162
k141_29265_4	SARG|gi|445996729|ref|WP_000074584.1|	40.1	227	294	309	3.28e-48	162
k141_29265_4	SARG|YP_001373621	39.2	227	294	318	4.12e-48	162
k141_29265_4	SARG|gi|507035724|ref|WP_016107411.1|	35.0	300	294	309	4.61e-48	161
k141_29265_4	SARG|gi|445996724|ref|WP_000074579.1|	40.1	227	294	309	4.61e-48	161
k141_29265_4	SARG|gi|884875933|emb|CKG93789.1|	40.1	227	294	309	4.61e-48	161
k141_12272_1	ResF|penA_1_AF515059_1	24.3	358	358	581	8.93e-09	55.8
k141_12272_16	SARG|gi|542061059|gb|ERI11611.1|	29.6	223	497	316	3.27e-15	75.5
k141_12272_16	SARG|gi|507055561|ref|WP_016126482.1|	28.6	241	497	309	9.91e-15	73.9
k141_12272_16	SARG|gi|488130770|ref|WP_002201978.1|	28.6	241	497	309	9.91e-15	73.9
k141_12272_16	SARG|gi|447057509|ref|WP_001134765.1|	29.0	241	497	309	9.91e-15	73.9
k141_12272_16	SARG|gi|445996719|ref|WP_000074574.1|	29.0	241	497	309	1.33e-14	73.6
k141_12272_16	SARG|gi|507050365|ref|WP_016121371.1|	28.8	243	497	309	1.33e-14	73.6
k141_12272_16	SARG|gi|507044560|ref|WP_016115614.1|	30.0	207	497	306	1.73e-14	73.2
k141_12272_16	SARG|gi|447057510|ref|WP_001134766.1|	29.0	241	497	309	1.79e-14	73.2
k141_12272_16	SARG|gi|446026113|ref|WP_000103968.1|	29.5	207	497	306	2.33e-14	72.8
k141_12272_16	SARG|gi|488053456|ref|WP_002124853.1|	28.6	241	497	309	2.40e-14	72.8
k141_12272_29	SARG|gi|542061059|gb|ERI11611.1|	29.8	205	362	316	2.16e-22	95.1
k141_12272_29	SARG|gi|445996719|ref|WP_000074574.1|	29.6	206	362	309	1.17e-20	90.1
k141_12272_29	SARG|gi|447057509|ref|WP_001134765.1|	28.2	206	362	309	1.17e-20	90.1
k141_12272_29	SARG|gi|507055561|ref|WP_016126482.1|	27.8	205	362	309	2.18e-20	89.4
k141_12272_29	SARG|gi|507050365|ref|WP_016121371.1|	27.7	220	362	309	4.08e-20	88.6
k141_12272_29	SARG|gi|488042066|ref|WP_002113463.1|	27.3	205	362	309	4.08e-20	88.6
k141_12272_29	SARG|gi|488068784|ref|WP_002140181.1|	28.3	205	362	309	4.08e-20	88.6
k141_12272_29	SARG|gi|507035724|ref|WP_016107411.1|	28.3	205	362	309	5.57e-20	88.2
k141_12272_29	SARG|gi|445996729|ref|WP_000074584.1|	29.1	206	362	309	5.57e-20	88.2
k141_12272_29	SARG|gi|895736250|emb|COF64653.1|	29.2	209	362	309	5.57e-20	88.2
k141_26131_8	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.3	226	221	230	1.32e-38	132
k141_26131_8	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.8	223	221	231	3.80e-38	131
k141_26131_8	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.3	223	221	231	2.12e-37	129
k141_26131_8	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.3	223	221	231	2.98e-37	129
k141_26131_8	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.7	225	221	229	1.12e-36	127
k141_26131_8	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.9	223	221	231	1.66e-36	127
k141_26131_8	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.1	220	221	228	2.16e-36	126
k141_26131_8	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	35.2	227	221	233	2.46e-36	126
k141_26131_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.5	219	221	219	6.77e-36	125
k141_26131_8	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	34.2	225	221	231	2.58e-35	124
k141_26131_9	SARG|gi|500194536|ref|WP_011867743.1|	43.4	304	305	306	3.05e-76	234
k141_26131_9	SARG|gi|542061059|gb|ERI11611.1|	42.1	304	305	316	4.68e-75	231
k141_26131_9	SARG|P42332	42.4	304	305	306	4.89e-75	231
k141_26131_9	SARG|ABB80128	42.4	304	305	306	6.92e-75	231
k141_26131_9	SARG|AAD21213	42.1	304	305	306	1.38e-74	230
k141_26131_9	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	42.5	301	305	306	1.38e-74	230
k141_26131_9	SARG|gi|510143239|gb|AGN36970.1|	42.5	301	305	313	1.71e-74	230
k141_26131_9	SARG|gi|447195835|ref|WP_001273091.1|	41.8	304	305	306	2.22e-73	227
k141_26131_9	SARG|gi|500448961|gb|EOP61695.1|	41.1	304	305	306	3.13e-73	226
k141_26131_9	SARG|gi|446026113|ref|WP_000103968.1|	40.5	306	305	306	3.13e-73	226
k141_26131_11	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.9	187	222	365	7.19e-14	68.6
k141_26131_11	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.2	170	222	370	3.38e-13	66.6
k141_26131_11	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.7	191	222	381	8.70e-13	65.5
k141_26131_11	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.7	191	222	381	8.70e-13	65.5
k141_26131_11	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.2	191	222	381	2.16e-12	64.3
k141_26131_11	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.2	191	222	381	2.16e-12	64.3
k141_26131_11	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	27.9	129	222	233	1.05e-08	52.8
k141_26131_11	megares|MEG_7508|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	129	222	233	1.05e-08	52.8
k141_26131_11	megares|MEG_7510|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.2	120	222	233	3.59e-08	51.2
k141_20353_2	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	25.7	401	492	451	5.69e-20	91.3
k141_20353_2	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	25.9	401	492	481	6.68e-20	91.3
k141_20353_5	SARG|gi|851935911|ref|WP_048224705.1|	34.9	195	201	660	7.78e-32	120
k141_20353_5	SARG|gi|757799830|ref|WP_043017032.1|	34.9	195	201	660	3.70e-31	118
k141_20353_5	SARG|gi|1002399350|ref|WP_061382108.1|	33.8	195	201	660	1.29e-30	116
k141_20353_5	SARG|gi|489931383|ref|WP_003834702.1|	35.0	197	201	660	1.29e-30	116
k141_20353_5	SARG|gi|489117806|ref|WP_003027650.1|	34.5	197	201	660	1.75e-30	116
k141_20353_5	SARG|gi|696375142|ref|WP_032949690.1|	34.5	197	201	660	1.75e-30	116
k141_20353_5	SARG|gi|851917461|ref|WP_048217311.1|	34.4	195	201	660	2.39e-30	115
k141_20353_5	SARG|gi|696369048|ref|WP_032944060.1|	34.5	197	201	660	2.39e-30	115
k141_20353_5	SARG|gi|507079934|ref|WP_016150692.1|	34.0	197	201	660	3.27e-30	115
k141_20353_5	SARG|YP_002850217	35.3	187	201	660	3.27e-30	115
k141_34695_23	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.3	227	504	258	7.32e-20	88.2
k141_34695_23	SARG|gb|AAK76137.1|ARO:3000024|patA	25.2	222	504	564	1.74e-12	68.6
k141_34695_23	ResF|poxtA-Ef_1_WP094899500.1_1	27.5	236	504	538	8.97e-12	66.2
k141_34695_23	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	27.5	236	504	543	9.04e-12	66.2
k141_34695_23	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	27.5	236	504	543	9.04e-12	66.2
k141_34695_23	SARG|gb|AAC75271.1|ARO:3003952|yojI	31.3	214	504	547	4.89e-11	63.9
k141_34695_23	SARG|gb|CDO61516.1|ARO:3003949|efrB	23.0	204	504	362	6.94e-11	62.8
k141_34695_23	SARG|gb|AVI44920.1|ARO:3004470|poxtA	30.0	170	504	542	6.02e-10	60.5
k141_34695_23	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	30.0	170	504	544	6.03e-10	60.5
k141_34695_23	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	26.6	218	504	550	1.06e-09	59.7
k141_20412_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.9	260	437	451	8.06e-29	116
k141_20412_2	CARD|gb|AEX49906.1|ARO:3003583|basS	29.7	327	437	477	6.43e-26	108
k141_20412_2	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	31.0	203	437	359	8.75e-22	95.1
k141_20412_2	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	29.1	251	437	364	4.76e-20	90.1
k141_20412_2	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	29.1	251	437	364	4.76e-20	90.1
k141_20412_2	CARD|gb|ADM92606.1|ARO:3000549|adeS	28.4	271	437	361	2.08e-19	88.2
k141_20412_2	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.9	204	437	392	6.69e-19	87.0
k141_20454_13	SARG|gb|BAD89844.2|ARO:3000753|abeM	23.8	353	449	448	6.58e-08	53.5
k141_15180_5	SARG|gb|BAG33043.1|ARO:3003920|pgpB	29.3	174	185	236	2.08e-08	51.2
k141_15180_5	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	28.7	174	185	236	5.28e-08	50.1
k141_15183_1	SARG|gi|1035706844|ref|WP_064548272.1|	36.4	77	795	648	6.56e-08	55.1
k141_3747_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	40.3	211	214	307	7.24e-45	150
k141_3747_6	SARG|gi|445996710|ref|WP_000074565.1|	39.2	209	214	309	6.53e-43	145
k141_3747_6	SARG|gi|445996719|ref|WP_000074574.1|	38.3	209	214	309	2.00e-41	141
k141_3747_6	SARG|gi|895736250|emb|COF64653.1|	38.3	209	214	309	2.00e-41	141
k141_3747_6	SARG|gi|446110087|ref|WP_000187942.1|	38.3	209	214	309	2.00e-41	141
k141_3747_6	SARG|gi|445996714|ref|WP_000074569.1|	38.3	209	214	309	2.00e-41	141
k141_3747_6	SARG|gi|500448961|gb|EOP61695.1|	37.9	211	214	306	5.19e-41	140
k141_3747_6	SARG|gi|445996722|ref|WP_000074577.1|	38.3	209	214	309	5.57e-41	140
k141_3747_6	SARG|gi|542061059|gb|ERI11611.1|	37.6	213	214	316	6.53e-41	140
k141_3747_6	SARG|gi|445996723|ref|WP_000074578.1|	37.8	209	214	309	7.83e-41	140
k141_23482_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.8	207	571	255	1.07e-22	96.7
k141_23482_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.1	223	571	307	1.38e-20	91.7
k141_23482_2	SARG|gi|1032819400|ref|WP_064325534.1|	32.9	228	571	646	1.68e-19	91.3
k141_23482_2	SARG|gi|749017716|ref|WP_040076354.1|	34.0	235	571	646	2.23e-19	90.9
k141_23482_2	SARG|gi|554685678|ref|WP_023185565.1|	31.5	235	571	648	2.24e-19	90.9
k141_23482_2	SARG|gi|976150171|ref|WP_059308384.1|	33.8	228	571	646	2.96e-19	90.5
k141_23482_2	SARG|gi|981224618|ref|WP_059445588.1|	33.8	228	571	646	2.96e-19	90.5
k141_23482_2	SARG|gi|895872463|ref|WP_048979698.1|	33.3	228	571	646	2.96e-19	90.5
k141_23482_2	SARG|gi|836585048|ref|WP_047742322.1|	33.8	228	571	646	2.96e-19	90.5
k141_23482_2	SARG|gi|695731723|ref|WP_032658224.1|	33.3	228	571	646	3.92e-19	90.1
k141_43682_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.4	71	99	219	6.75e-06	41.6
k141_34893_5	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	38.0	221	227	231	1.20e-44	148
k141_34893_5	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	37.1	221	227	233	1.79e-44	147
k141_34893_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.5	220	227	219	2.12e-39	134
k141_34893_5	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.8	222	227	219	1.03e-36	127
k141_34893_5	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	222	227	219	4.09e-36	125
k141_34893_5	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	222	227	220	4.19e-36	125
k141_34893_5	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.3	222	227	220	5.91e-36	125
k141_34893_5	SARG|ZP_02848503	34.7	225	227	221	6.69e-35	122
k141_34893_5	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	227	227	220	1.29e-34	122
k141_34893_5	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	32.6	218	227	225	2.07e-34	121
k141_15349_1	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	40.0	220	235	255	2.96e-56	179
k141_15349_1	SARG|gi|495736522|ref|WP_008461101.1|	45.2	219	235	648	5.49e-53	179
k141_15349_1	SARG|gi|746253210|ref|WP_039301529.1|	45.2	219	235	648	5.49e-53	179
k141_15349_1	SARG|gi|746243059|ref|WP_039291473.1|	45.7	219	235	648	7.63e-53	179
k141_15349_1	SARG|YP_001588793	44.4	225	235	648	7.63e-53	179
k141_15349_1	SARG|gi|1001720867|ref|WP_061274204.1|	45.2	219	235	648	1.06e-52	179
k141_15349_1	SARG|gi|639225329|ref|WP_024561799.1|	45.2	219	235	648	1.47e-52	178
k141_15349_1	SARG|gi|696368937|ref|WP_032943949.1|	42.9	231	235	648	1.47e-52	178
k141_15349_1	SARG|gi|851913025|ref|WP_048215946.1|	42.9	231	235	648	1.47e-52	178
k141_15349_1	SARG|YP_002850060	42.9	231	235	648	1.47e-52	178
k141_3957_2	CARD|gb|BAB36671.1|ARO:3000832|evgA	24.1	116	357	204	1.12e-06	47.8
k141_3957_4	ResF|mre(A)_1_U92073_1	30.7	313	300	310	1.54e-38	137
k141_3957_4	SARG|gb|AAB64408.1|ARO:3007050|mreA	30.7	313	300	311	1.57e-38	137
k141_29560_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	48.7	228	234	228	2.10e-68	209
k141_29560_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.3	227	234	231	5.91e-61	190
k141_29560_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.5	232	234	232	4.91e-60	187
k141_29560_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.1	232	234	232	1.97e-59	186
k141_29560_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.6	229	234	232	3.95e-59	185
k141_29560_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.6	229	234	232	3.95e-59	185
k141_29560_2	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.7	232	234	232	7.91e-59	184
k141_29560_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.1	228	234	232	2.24e-58	183
k141_29560_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.1	233	234	235	9.85e-58	182
k141_29560_2	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.5	232	234	232	1.80e-57	181
k141_29560_3	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.2	227	468	381	1.22e-31	124
k141_29560_3	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.2	227	468	381	1.22e-31	124
k141_29560_3	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.8	250	468	381	1.70e-28	115
k141_29560_3	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.8	250	468	381	1.70e-28	115
k141_29560_3	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	250	468	381	8.10e-28	113
k141_29560_3	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	250	468	381	8.10e-28	113
k141_29560_3	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	250	468	381	2.06e-27	112
k141_29560_3	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	250	468	381	2.06e-27	112
k141_29560_3	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.0	250	468	381	3.83e-27	111
k141_29560_3	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.0	250	468	381	3.83e-27	111
k141_20710_8	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	24.3	300	711	579	7.18e-25	108
k141_20710_8	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	24.7	300	711	579	9.54e-25	108
k141_20710_8	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	26.2	233	711	578	3.15e-19	90.9
k141_20710_12	SARG|gi|446026113|ref|WP_000103968.1|	47.2	214	224	306	7.61e-57	181
k141_20710_12	SARG|gi|500448961|gb|EOP61695.1|	47.7	214	224	306	3.03e-56	180
k141_20710_12	SARG|gi|500465078|gb|EOP76697.1|	47.7	214	224	306	3.03e-56	180
k141_20710_12	SARG|gi|500194536|ref|WP_011867743.1|	46.3	214	224	306	6.05e-56	179
k141_20710_12	SARG|gi|507044560|ref|WP_016115614.1|	46.7	214	224	306	6.05e-56	179
k141_20710_12	SARG|gi|445996722|ref|WP_000074577.1|	46.7	214	224	309	9.27e-56	179
k141_20710_12	SARG|ABB80128	45.8	214	224	306	1.21e-55	178
k141_20710_12	SARG|gi|445996723|ref|WP_000074578.1|	46.7	214	224	309	1.31e-55	178
k141_20710_12	SARG|gi|445996719|ref|WP_000074574.1|	46.3	214	224	309	1.85e-55	178
k141_20710_12	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	44.5	229	224	307	2.48e-55	177
k141_20710_18	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.3	551	578	582	1.23e-74	247
k141_20710_18	SARG|gi|1033217078|gb|OAR27197.1|	31.5	495	578	601	2.98e-69	233
k141_20710_18	SARG|gi|860594225|ref|WP_048475168.1|	30.1	498	578	620	4.39e-69	233
k141_20710_18	SARG|gi|926376632|ref|WP_053705806.1|	30.5	498	578	620	1.65e-68	232
k141_20710_18	SARG|gi|496018010|ref|WP_008742581.1|	30.3	492	578	623	1.75e-68	232
k141_20710_18	SARG|gi|664579989|ref|WP_031094015.1|	30.5	495	578	601	4.22e-68	230
k141_20710_18	SARG|gi|664556405|ref|WP_031071225.1|	29.7	488	578	602	4.31e-68	230
k141_20710_18	SARG|gi|917166849|ref|WP_051773561.1|	29.7	536	578	620	4.44e-68	231
k141_20710_18	SARG|gi|799286378|ref|WP_045936958.1|	30.3	498	578	620	4.44e-68	231
k141_20710_18	SARG|gi|917127754|ref|WP_051734466.1|	30.3	498	578	620	4.44e-68	231
k141_20710_19	SARG|gi|695842130|ref|WP_032755430.1|	29.8	590	605	603	1.87e-75	251
k141_20710_19	SARG|gi|505420018|ref|WP_015607120.1|	29.8	590	605	603	1.87e-75	251
k141_20710_19	SARG|gi|648667297|ref|WP_026359044.1|	30.6	585	605	605	3.81e-75	250
k141_20710_19	SARG|gi|944152509|ref|WP_055644808.1|	29.7	630	605	616	9.42e-75	249
k141_20710_19	SARG|gi|664556405|ref|WP_031071225.1|	29.5	603	605	602	9.68e-75	249
k141_20710_19	SARG|gi|860594225|ref|WP_048475168.1|	31.4	507	605	620	1.43e-74	249
k141_20710_19	SARG|gi|944009777|ref|WP_055601444.1|	29.1	608	605	628	1.24e-73	246
k141_20710_19	SARG|gi|663350985|ref|WP_030349761.1|	29.3	591	605	613	2.45e-73	245
k141_20710_19	SARG|gi|517347347|ref|WP_018522839.1|	29.3	610	605	601	2.64e-73	245
k141_20710_19	SARG|gi|655401130|ref|WP_028800283.1|	46.6	262	605	599	3.52e-73	244
k141_20710_21	SARG|gi|921979807|ref|WP_053271336.1|	32.7	226	496	648	4.64e-20	92.4
k141_20710_21	SARG|gi|740610794|ref|WP_038396317.1|	28.6	231	496	648	2.78e-14	74.3
k141_20710_21	SARG|gb|AVI44920.1|ARO:3004470|poxtA	24.2	363	496	542	9.70e-14	72.4
k141_20710_21	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	24.2	363	496	544	9.73e-14	72.4
k141_20710_21	SARG|gi|860594225|ref|WP_048475168.1|	30.9	188	496	620	1.36e-12	68.9
k141_20710_21	SARG|gi|516574297|ref|WP_017949361.1|	27.9	262	496	620	1.36e-12	68.9
k141_20710_21	SARG|gi|739906046|ref|WP_037756452.1|	27.5	258	496	620	2.39e-12	68.2
k141_20710_21	SARG|gi|493394434|ref|WP_006350564.1|	29.0	217	496	602	3.09e-12	67.8
k141_20710_21	SARG|gi|926351744|ref|WP_053683383.1|	30.9	188	496	648	7.53e-12	66.6
k141_20710_21	SARG|gi|736472622|ref|WP_034494292.1|	25.9	243	496	648	9.96e-12	66.2
k141_20722_2	SARG|ZP_04528247	61.0	272	276	279	1.73e-107	311
k141_20722_2	SARG|ZP_03941859	56.4	275	276	288	1.37e-101	297
k141_20722_2	SARG|ZP_03938934	56.4	275	276	288	1.37e-101	297
k141_20722_2	SARG|ZP_03945515	56.7	275	276	291	2.47e-100	294
k141_20722_2	SARG|ZP_04433866	55.8	265	276	288	3.65e-99	291
k141_20722_2	SARG|ZP_03949893	55.8	265	276	288	3.65e-99	291
k141_20722_2	SARG|ZP_03984017	55.5	265	276	288	7.33e-99	290
k141_20722_2	SARG|ZP_03958019	54.5	279	276	317	1.25e-96	285
k141_20722_2	SARG|YP_002929946	56.0	273	276	282	1.60e-96	284
k141_20722_2	SARG|YP_002937728	50.7	278	276	289	1.74e-87	261
k141_20722_5	SARG|gi|695793471|ref|WP_032707680.1|	36.8	220	248	648	1.20e-41	149
k141_20722_5	SARG|gi|823302270|ref|WP_047057473.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|976146774|ref|WP_059305359.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|1022664304|ref|WP_063420886.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|823309640|ref|WP_047064288.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|505807117|ref|WP_015704872.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|505180394|ref|WP_015367496.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|518923394|ref|WP_020079269.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|695797094|ref|WP_032711285.1|	36.8	220	248	648	1.66e-41	149
k141_20722_5	SARG|gi|896325272|ref|WP_049294291.1|	40.2	204	248	648	1.66e-41	149
k141_20722_6	SARG|YP_002850805	33.1	472	447	652	4.88e-73	241
k141_20722_6	SARG|ZP_02952732	33.0	467	447	652	1.86e-72	239
k141_20722_6	SARG|ZP_02632674	33.0	467	447	660	2.17e-72	239
k141_20722_6	SARG|L20800.gene.p01	33.0	467	447	652	3.63e-72	238
k141_20722_6	SARG|L42544.gene.p01	34.1	472	447	651	4.98e-72	238
k141_20722_6	SARG|AAV80410	33.9	472	447	651	1.01e-70	234
k141_20722_6	SARG|NP_348076	32.8	473	447	652	2.00e-70	234
k141_20722_6	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	32.4	457	447	641	2.26e-70	233
k141_20722_6	SARG|AAZ79478	32.4	457	447	657	3.07e-70	233
k141_20722_6	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	33.0	458	447	654	2.14e-69	231
k141_37996_1	SARG|L42544.gene.p01	33.3	171	457	651	3.39e-21	95.5
k141_37996_1	SARG|AAV80410	33.3	171	457	651	3.39e-21	95.5
k141_37996_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	40.7	231	233	231	7.71e-56	177
k141_37996_7	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.2	230	233	232	7.94e-56	177
k141_37996_7	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.0	229	233	229	1.06e-52	169
k141_37996_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.2	229	233	232	7.40e-51	164
k141_37996_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.2	229	233	232	7.40e-51	164
k141_37996_7	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.1	232	233	232	1.05e-50	164
k141_37996_7	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.5	232	233	233	4.30e-50	162
k141_37996_7	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.6	230	233	231	3.24e-49	160
k141_37996_7	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.0	229	233	231	1.29e-48	158
k141_37996_7	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	233	231	1.29e-48	158
k141_37996_8	SARG|gi|542061059|gb|ERI11611.1|	42.9	303	309	316	1.52e-74	230
k141_37996_8	SARG|P42332	40.9	303	309	306	2.02e-72	224
k141_37996_8	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	40.9	303	309	306	2.02e-72	224
k141_37996_8	SARG|gi|510143239|gb|AGN36970.1|	40.9	303	309	313	2.50e-72	224
k141_37996_8	SARG|ABB80128	40.6	303	309	306	1.62e-71	222
k141_37996_8	SARG|AAD21213	40.6	303	309	306	3.23e-71	221
k141_37996_8	SARG|YP_001373621	39.9	303	309	318	2.33e-68	214
k141_37996_8	SARG|gi|500194536|ref|WP_011867743.1|	39.9	303	309	306	3.27e-68	214
k141_37996_8	SARG|gi|446026113|ref|WP_000103968.1|	38.6	303	309	306	7.34e-67	210
k141_37996_8	SARG|gi|507044560|ref|WP_016115614.1|	38.6	303	309	306	2.92e-66	209
k141_37996_12	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	30.4	237	316	370	4.94e-25	102
k141_37996_12	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.3	201	316	354	5.21e-24	99.4
k141_37996_12	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	201	316	352	1.82e-23	97.8
k141_37996_12	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.5	236	316	354	1.86e-23	97.8
k141_37996_12	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.2	276	316	365	2.12e-23	97.8
k141_37996_12	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	201	316	376	2.40e-23	97.8
k141_37996_12	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	29.9	201	316	376	2.40e-23	97.8
k141_37996_12	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.5	287	316	361	1.86e-22	95.1
k141_37996_12	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	26.5	287	316	361	1.86e-22	95.1
k141_37996_12	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	26.5	287	316	361	2.55e-22	94.7
k141_26161_2	CARD|gb|ABD30512.1|ARO:3000839|arlS	26.9	409	455	451	2.56e-26	109
k141_26161_2	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	25.9	263	455	392	7.58e-19	87.0
k141_26161_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.6	219	225	219	8.90e-58	181
k141_26161_3	CARD|gb|AAG06465.1|ARO:3005063|cprR	36.2	218	225	223	6.36e-45	148
k141_26161_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.6	226	225	232	2.89e-42	142
k141_26161_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.8	223	225	231	3.96e-42	141
k141_26161_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.9	218	225	228	2.05e-41	139
k141_26161_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	218	225	219	2.81e-39	134
k141_26161_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	218	225	220	2.89e-39	134
k141_26161_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	218	225	220	5.75e-39	133
k141_26161_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	218	225	219	2.22e-38	131
k141_26161_3	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.5	218	225	220	6.39e-38	130
k141_1234_11	SARG|gi|639209604|ref|WP_024547784.1|	30.4	224	495	648	1.95e-20	93.6
k141_1234_11	SARG|gi|542061059|gb|ERI11611.1|	29.4	252	495	316	2.26e-16	79.0
k141_1234_11	SARG|gi|510143239|gb|AGN36970.1|	27.1	236	495	313	7.63e-15	74.3
k141_1234_11	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	22.8	224	495	343	1.81e-14	73.6
k141_1234_11	SARG|ZP_04081918	28.4	236	495	306	2.31e-14	72.8
k141_1234_11	SARG|P42332	27.8	212	495	306	5.60e-14	71.6
k141_1234_11	SARG|ABB80128	27.8	212	495	306	5.60e-14	71.6
k141_1234_11	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	27.8	212	495	306	5.60e-14	71.6
k141_1234_11	SARG|gi|447057509|ref|WP_001134765.1|	28.5	235	495	309	7.75e-14	71.2
k141_1234_11	SARG|gi|507055561|ref|WP_016126482.1|	28.9	235	495	309	1.04e-13	70.9
k141_20787_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.5	247	457	885	1.35e-08	56.2
k141_20787_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.9	217	220	228	8.59e-39	132
k141_20787_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.1	223	220	231	7.32e-38	130
k141_20787_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	226	220	231	2.05e-37	129
k141_20787_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	33.3	222	220	225	6.00e-35	122
k141_20787_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.3	219	220	225	1.19e-34	122
k141_20787_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.5	220	220	219	7.99e-34	119
k141_20787_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.0	220	220	220	1.63e-33	119
k141_20787_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.0	220	220	219	3.15e-33	118
k141_20787_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.0	220	220	220	3.23e-33	118
k141_20787_2	SARG|ZP_02848503	34.7	219	220	221	4.66e-33	117
k141_20787_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	57.1	35	52	307	1.90e-06	41.2
k141_20787_5	SARG|gi|542061059|gb|ERI11611.1|	47.1	51	52	316	2.60e-06	40.8
k141_40452_5	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.6	203	237	307	1.59e-19	84.3
k141_40452_5	SARG|gb|AAK76137.1|ARO:3000024|patA	25.7	237	237	564	2.62e-12	64.7
k141_40452_7	SARG|gb|AAA85213.1|ARO:3002866|dfrD	40.0	165	164	162	2.34e-31	109
k141_40452_7	megares|MEG_2575|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	40.0	165	164	162	2.34e-31	109
k141_40452_7	megares|MEG_2574|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	40.0	165	164	166	2.61e-31	109
k141_40452_7	SARG|gb|BAE15963.1|ARO:3002868|dfrG	37.2	164	164	165	1.44e-30	107
k141_40452_7	megares|MEG_2576|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRD_1	39.9	158	164	154	1.20e-29	105
k141_40452_7	SARG|CAL48457	38.1	134	164	183	5.25e-22	86.3
k141_40452_7	NCBI|WP_034702334.1|1|1|dfrA40|dfrA40|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA40|AMR|diaminopyrimidine	35.1	134	164	170	1.82e-19	79.3
k141_40452_7	SARG|CAI99385	36.6	131	164	185	5.30e-18	75.9
k141_40452_7	NCBI|WP_004729503.1|1|1|dfrA41|dfrA41|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA41|AMR|diaminopyrimidine	29.5	166	164	170	1.07e-17	74.7
k141_40452_7	NCBI|WP_031380727.1|1|1|dfrA44|dfrA44|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA44|AMR|diaminopyrimidine	32.8	134	164	170	1.51e-17	74.3
k141_35108_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	38.1	189	189	648	7.00e-35	128
k141_35108_1	NCBI|WP_000052512.1|1|1|msr(E)|msr(E)|target_protection|2|AZITHROMYCIN/ERYTHROMYCIN/STREPTOGRAMIN|MACROLIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Msr(E)|AMR|multidrug	44.0	75	189	491	2.68e-13	66.2
k141_35108_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_35108_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_35108_1	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_35108_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_35108_1	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_35108_1	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_35108_1	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_35108_1	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	41.3	80	189	655	2.45e-12	63.5
k141_38112_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.3	259	868	370	2.93e-30	122
k141_38112_3	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	31.5	286	868	368	1.27e-29	120
k141_38112_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.3	276	868	365	1.62e-29	120
k141_38112_3	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	31.4	261	868	367	1.02e-28	117
k141_38112_3	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.2	276	868	381	4.61e-27	113
k141_38112_3	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.2	276	868	381	4.61e-27	113
k141_38112_3	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.9	291	868	381	8.37e-27	112
k141_38112_3	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.9	291	868	381	8.37e-27	112
k141_38112_3	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.7	283	868	381	1.13e-26	112
k141_38112_3	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.7	283	868	381	1.13e-26	112
k141_38112_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	41.8	122	120	239	1.92e-30	107
k141_38112_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.2	119	120	232	9.16e-30	105
k141_38112_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.2	119	120	232	9.16e-30	105
k141_38112_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.5	119	120	229	1.70e-29	105
k141_38112_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.4	119	120	231	2.51e-29	104
k141_38112_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.4	119	120	231	2.51e-29	104
k141_38112_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.9	119	120	231	1.97e-28	102
k141_38112_4	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.9	119	120	231	1.97e-28	102
k141_38112_4	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.0	119	120	231	2.18e-27	99.8
k141_38112_4	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.5	118	120	231	2.18e-27	99.8
k141_35120_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	70.9	306	309	307	1.01e-152	429
k141_35120_3	SARG|gi|445996710|ref|WP_000074565.1|	53.2	301	309	309	1.13e-101	299
k141_35120_3	SARG|gi|445996719|ref|WP_000074574.1|	52.8	301	309	309	1.60e-101	299
k141_35120_3	SARG|gi|445996708|ref|WP_000074563.1|	52.8	301	309	309	1.60e-101	299
k141_35120_3	SARG|YP_001373621	52.2	299	309	318	2.15e-101	299
k141_35120_3	SARG|gi|814314593|emb|CKF49145.1|	53.2	301	309	309	4.56e-101	298
k141_35120_3	SARG|gi|895736250|emb|COF64653.1|	52.8	301	309	309	6.46e-101	297
k141_35120_3	SARG|gi|445996714|ref|WP_000074569.1|	52.8	301	309	309	6.46e-101	297
k141_35120_3	SARG|gi|895808656|emb|COR83787.1|	52.8	301	309	309	6.46e-101	297
k141_35120_3	SARG|gi|542061059|gb|ERI11611.1|	52.5	299	309	316	8.13e-101	297
k141_38133_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	220	224	219	1.58e-55	175
k141_38133_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	220	224	220	1.63e-55	175
k141_38133_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	220	224	220	2.31e-55	175
k141_38133_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.0	220	224	219	1.27e-54	173
k141_38133_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.5	220	224	220	1.05e-53	171
k141_38133_2	SARG|ZP_02848503	38.2	217	224	221	6.16e-53	169
k141_38133_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.3	223	224	228	1.40e-47	155
k141_38133_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.7	218	224	219	4.37e-44	146
k141_38133_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.8	225	224	232	4.40e-41	139
k141_38133_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.6	234	224	235	5.31e-40	136
k141_38133_3	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	31.1	334	458	447	3.36e-37	140
k141_38133_3	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	31.1	334	458	447	4.63e-37	140
k141_38133_3	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	31.9	298	458	447	6.38e-37	139
k141_38133_3	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.8	334	458	447	1.67e-36	138
k141_38133_3	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	30.5	334	458	454	2.37e-35	135
k141_38133_3	NCBI|WP_063856737.1|1|1|vanS-B-Delta|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|VanB-type_glycopeptide_resistance_histidine_kinase_VanS-B-Delta|AMR|glycopeptide	30.8	334	458	441	4.70e-34	131
k141_38133_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.8	212	458	359	2.14e-20	91.3
k141_38133_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.1	255	458	364	3.84e-17	81.6
k141_38133_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.1	255	458	364	3.84e-17	81.6
k141_38205_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.7	549	580	575	6.73e-127	383
k141_38205_2	SARG|gb|AAK76137.1|ARO:3000024|patA	33.5	570	580	564	1.37e-98	310
k141_38205_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.3	527	580	664	1.70e-58	206
k141_38205_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.3	587	580	579	1.45e-57	201
k141_38205_2	SARG|gb|AAK76136.1|ARO:3000025|patB	26.8	583	580	588	1.70e-57	201
k141_38205_2	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.9	559	580	574	6.55e-56	197
k141_38205_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.1	583	580	579	7.16e-56	197
k141_38205_2	SARG|gi|516574297|ref|WP_017949361.1|	26.3	539	580	620	4.10e-51	184
k141_38205_2	SARG|gi|739906046|ref|WP_037756452.1|	26.0	539	580	620	2.77e-50	182
k141_38205_2	SARG|gi|928900436|ref|WP_053931243.1|	26.3	540	580	600	1.41e-49	180
k141_38205_3	SARG|gb|AAK76136.1|ARO:3000025|patB	33.0	539	581	588	4.78e-95	301
k141_38205_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	34.3	522	581	664	5.89e-95	303
k141_38205_3	SARG|gi|947982677|ref|WP_056642336.1|	31.6	573	581	626	7.60e-87	281
k141_38205_3	SARG|gi|944152509|ref|WP_055644808.1|	31.3	578	581	616	8.39e-87	280
k141_38205_3	SARG|gi|639892676|ref|WP_024755698.1|	31.6	573	581	631	8.55e-87	281
k141_38205_3	SARG|gi|860594225|ref|WP_048475168.1|	32.1	574	581	620	4.98e-86	278
k141_38205_3	SARG|gi|944009777|ref|WP_055601444.1|	31.1	578	581	628	6.01e-86	278
k141_38205_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	45.7	315	581	362	7.74e-86	270
k141_38205_3	SARG|gi|1045390184|ref|WP_065479071.1|	31.9	577	581	605	1.88e-85	276
k141_38205_3	SARG|gi|928900436|ref|WP_053931243.1|	31.1	572	581	600	4.57e-85	275
k141_6741_3	SARG|gi|505420018|ref|WP_015607120.1|	30.1	375	533	603	4.00e-35	138
k141_6741_3	SARG|gi|695842130|ref|WP_032755430.1|	29.9	375	533	603	1.34e-34	136
k141_6741_3	SARG|gi|496018010|ref|WP_008742581.1|	31.1	373	533	623	3.81e-34	135
k141_6741_3	SARG|gi|662754041|ref|WP_030125200.1|	30.3	373	533	601	6.00e-34	134
k141_6741_3	SARG|gi|702897513|ref|WP_033300957.1|	30.9	375	533	601	6.00e-34	134
k141_6741_3	SARG|gi|505389066|ref|WP_015576168.1|	30.3	373	533	601	6.00e-34	134
k141_6741_3	SARG|gi|1045390184|ref|WP_065479071.1|	29.7	374	533	605	6.17e-34	134
k141_6741_3	SARG|gi|860594225|ref|WP_048475168.1|	31.1	373	533	620	6.81e-34	134
k141_6741_3	SARG|gi|503923650|ref|WP_014157644.1|	30.3	373	533	601	8.12e-34	134
k141_6741_3	SARG|gi|664170108|ref|WP_030704355.1|	30.7	375	533	603	8.23e-34	134
k141_6741_12	SARG|gb|AAK76136.1|ARO:3000025|patB	23.3	559	578	588	3.20e-46	170
k141_6741_12	SARG|gi|664170108|ref|WP_030704355.1|	36.3	267	578	603	3.53e-45	167
k141_6741_12	SARG|gi|930482089|ref|WP_054228897.1|	34.8	270	578	599	6.28e-45	167
k141_6741_12	SARG|gi|985844137|ref|WP_060895163.1|	34.8	270	578	599	6.28e-45	167
k141_6741_12	SARG|gi|695865802|ref|WP_032778631.1|	35.6	267	578	605	9.27e-45	166
k141_6741_12	SARG|gi|928900436|ref|WP_053931243.1|	36.5	266	578	600	1.19e-44	166
k141_6741_12	SARG|gi|664579989|ref|WP_031094015.1|	36.5	266	578	601	1.21e-44	166
k141_6741_12	SARG|gi|490068471|ref|WP_003970646.1|	36.0	267	578	603	1.24e-44	166
k141_6741_12	SARG|gi|1045390184|ref|WP_065479071.1|	36.0	267	578	605	1.27e-44	166
k141_6741_12	SARG|gi|947982677|ref|WP_056642336.1|	36.4	269	578	626	1.62e-44	166
k141_6741_13	SARG|gi|926351744|ref|WP_053683383.1|	40.2	264	553	648	6.94e-51	184
k141_6741_13	SARG|gi|860594225|ref|WP_048475168.1|	39.4	264	553	620	8.98e-51	183
k141_6741_13	SARG|gi|664042835|ref|WP_030582300.1|	33.0	361	553	604	9.82e-51	182
k141_6741_13	SARG|gi|664170108|ref|WP_030704355.1|	35.9	295	553	603	1.33e-50	182
k141_6741_13	SARG|gi|917166849|ref|WP_051773561.1|	39.4	264	553	620	1.70e-50	182
k141_6741_13	SARG|gi|917155568|ref|WP_051762280.1|	39.4	264	553	620	2.34e-50	182
k141_6741_13	SARG|gi|1045390184|ref|WP_065479071.1|	35.4	288	553	605	2.60e-50	181
k141_6741_13	SARG|gi|517787730|ref|WP_018957938.1|	36.1	288	553	610	2.80e-50	181
k141_6741_13	SARG|gi|490068471|ref|WP_003970646.1|	36.1	288	553	603	3.48e-50	181
k141_6741_13	SARG|gi|662175949|ref|WP_030118884.1|	36.1	288	553	605	3.59e-50	181
k141_6751_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	34.1	220	288	307	7.22e-33	121
k141_6751_6	SARG|gi|542061059|gb|ERI11611.1|	29.8	289	288	316	4.59e-32	119
k141_6751_6	SARG|gi|447195835|ref|WP_001273091.1|	30.6	271	288	306	2.05e-30	115
k141_6751_6	SARG|gi|447195836|ref|WP_001273092.1|	30.3	271	288	306	5.55e-30	114
k141_6751_6	SARG|ZP_04081918	32.6	224	288	306	2.09e-29	112
k141_6751_6	SARG|gi|500194536|ref|WP_011867743.1|	34.4	224	288	306	2.91e-29	112
k141_6751_6	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	28.9	242	288	343	4.94e-24	98.6
k141_6751_6	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.2	224	288	579	6.19e-11	61.6
k141_6751_6	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.2	224	288	579	8.29e-11	61.2
k141_6751_6	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.4	159	288	362	2.05e-09	56.6
k141_6938_8	SARG|gb|WP_104671188.1|ARO:3003948|efrA	23.8	227	258	575	8.57e-13	66.6
k141_6938_8	SARG|gi|1045390184|ref|WP_065479071.1|	25.0	200	258	605	3.87e-12	64.7
k141_6938_8	SARG|gi|497748188|ref|WP_010062372.1|	25.0	200	258	605	9.43e-12	63.5
k141_6938_8	SARG|gi|764446018|ref|WP_044369325.1|	24.5	200	258	605	1.27e-11	63.2
k141_6938_8	SARG|gi|695887424|ref|WP_032788534.1|	24.5	200	258	605	1.71e-11	62.8
k141_6938_8	SARG|gi|695865802|ref|WP_032778631.1|	24.5	200	258	605	1.71e-11	62.8
k141_6938_8	SARG|gi|664180077|ref|WP_030714054.1|	24.5	200	258	605	1.71e-11	62.8
k141_6938_8	SARG|gi|1033151784|ref|WP_064457526.1|	26.6	184	258	614	2.31e-11	62.4
k141_6938_8	SARG|gi|987887954|ref|WP_060953374.1|	26.6	184	258	614	2.31e-11	62.4
k141_6938_8	SARG|gi|664304639|ref|WP_030834011.1|	26.6	184	258	614	2.31e-11	62.4
k141_6938_11	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.4	545	578	575	5.60e-108	334
k141_6938_11	SARG|gb|AAK76137.1|ARO:3000024|patA	34.6	572	578	564	6.56e-99	310
k141_6938_11	SARG|gi|739906046|ref|WP_037756452.1|	29.1	547	578	620	4.27e-60	209
k141_6938_11	SARG|gi|516574297|ref|WP_017949361.1|	29.1	547	578	620	4.27e-60	209
k141_6938_11	SARG|gi|860594225|ref|WP_048475168.1|	27.4	558	578	620	8.18e-60	208
k141_6938_11	SARG|gi|1045390184|ref|WP_065479071.1|	27.3	568	578	605	4.44e-59	206
k141_6938_11	SARG|gb|CDO61516.1|ARO:3003949|efrB	36.7	332	578	362	5.52e-59	199
k141_6938_11	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.1	494	578	664	6.18e-59	207
k141_6938_11	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	29.9	499	578	574	6.71e-59	205
k141_6938_11	SARG|gi|944470764|ref|WP_055701183.1|	28.1	572	578	601	7.94e-59	205
k141_6938_12	SARG|gb|AAK76136.1|ARO:3000025|patB	29.6	476	490	588	6.93e-48	173
k141_6938_12	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.1	473	490	579	3.05e-47	171
k141_6938_12	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	25.7	474	490	579	1.34e-44	164
k141_6938_12	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.0	418	490	664	8.79e-44	162
k141_6938_12	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.7	487	490	578	2.93e-42	157
k141_6938_12	SARG|gb|WP_104671188.1|ARO:3003948|efrA	26.9	476	490	575	1.23e-37	144
k141_6938_12	SARG|gb|CDO61516.1|ARO:3003949|efrB	31.7	290	490	362	3.24e-37	139
k141_6938_12	SARG|gb|AAK76137.1|ARO:3000024|patA	28.9	433	490	564	3.99e-35	137
k141_6938_12	SARG|gi|948137056|ref|WP_056795395.1|	23.5	455	490	602	2.51e-34	135
k141_6938_12	SARG|gi|664317010|ref|WP_030845774.1|	23.7	455	490	605	2.56e-34	135
k141_38357_2	SARG|gb|AAV85982.1|ARO:3000535|macB	40.6	217	596	644	1.55e-33	134
k141_38357_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	29.2	212	596	579	5.00e-19	89.7
k141_21078_2	SARG|gi|648667297|ref|WP_026359044.1|	32.4	577	574	605	7.94e-96	303
k141_21078_2	SARG|gi|928900436|ref|WP_053931243.1|	32.0	578	574	600	1.38e-95	303
k141_21078_2	SARG|gi|664579989|ref|WP_031094015.1|	32.0	578	574	601	1.41e-95	303
k141_21078_2	SARG|gi|662754041|ref|WP_030125200.1|	32.0	575	574	601	1.98e-95	302
k141_21078_2	SARG|gi|951183771|ref|WP_057661487.1|	31.5	575	574	603	2.09e-95	302
k141_21078_2	SARG|gi|664170108|ref|WP_030704355.1|	31.5	575	574	603	2.93e-95	302
k141_21078_2	SARG|gi|497748188|ref|WP_010062372.1|	31.3	575	574	605	3.09e-95	302
k141_21078_2	SARG|gi|764446018|ref|WP_044369325.1|	31.3	575	574	605	3.09e-95	302
k141_21078_2	SARG|gi|1045390184|ref|WP_065479071.1|	31.3	575	574	605	3.09e-95	302
k141_21078_2	SARG|gi|503923650|ref|WP_014157644.1|	32.0	575	574	601	3.91e-95	301
k141_21099_1	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	39.2	153	152	307	8.38e-35	122
k141_21099_1	SARG|gb|AAV85982.1|ARO:3000535|macB	25.5	161	152	644	9.29e-09	52.0
k141_21099_1	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.6	162	152	579	2.24e-06	45.1
k141_21099_1	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	37.7	69	152	579	4.13e-06	44.3
k141_21099_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.0	227	223	231	2.35e-43	144
k141_21099_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	33.6	232	223	229	3.93e-41	139
k141_21099_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.8	233	223	235	1.30e-40	137
k141_21099_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.9	223	223	231	9.20e-40	135
k141_21099_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.0	223	223	232	2.65e-39	134
k141_21099_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	36.2	224	223	247	2.78e-39	134
k141_21099_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.5	222	223	219	5.85e-38	130
k141_21099_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	33.8	228	223	233	8.46e-38	130
k141_21099_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.8	229	223	231	1.60e-37	129
k141_21099_2	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.6	226	223	230	2.19e-37	129
k141_7117_14	SARG|gi|507044560|ref|WP_016115614.1|	34.2	316	324	306	5.94e-54	177
k141_7117_14	SARG|P42332	35.6	315	324	306	8.37e-54	177
k141_7117_14	SARG|AAD21213	35.9	315	324	306	8.37e-54	177
k141_7117_14	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	35.6	315	324	306	8.37e-54	177
k141_7117_14	SARG|gi|510143239|gb|AGN36970.1|	35.6	315	324	313	1.01e-53	177
k141_7117_14	SARG|ABB80128	35.6	315	324	306	2.34e-53	176
k141_7117_14	SARG|gi|447195835|ref|WP_001273091.1|	43.5	223	324	306	1.82e-52	174
k141_7117_14	SARG|gi|446026113|ref|WP_000103968.1|	33.9	316	324	306	2.57e-52	173
k141_7117_14	SARG|ZP_04081918	34.9	315	324	306	5.09e-52	172
k141_7117_14	SARG|gi|447195836|ref|WP_001273092.1|	43.0	223	324	306	5.09e-52	172
k141_40819_1	SARG|CAA37477	41.1	151	359	663	2.15e-23	100
k141_40819_1	SARG|AAV80410	24.9	397	359	651	9.39e-23	98.6
k141_40819_1	SARG|ABV82118	23.9	414	359	639	4.09e-22	96.7
k141_40819_1	SARG|ZP_03989103	24.2	414	359	639	5.50e-22	96.3
k141_40819_1	SARG|ABV82120	24.2	414	359	639	5.50e-22	96.3
k141_40819_1	SARG|L42544.gene.p01	24.7	397	359	651	5.57e-22	96.3
k141_40819_1	SARG|gi|1004359922|gb|AMP42228.1|	25.6	414	359	639	7.39e-22	95.9
k141_40819_1	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	419	359	629	1.78e-21	94.7
k141_40819_1	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.0	419	359	629	1.78e-21	94.7
k141_40819_1	ResF|tet(O/W)_3_AM889120_1	26.0	419	359	639	1.80e-21	94.7
k141_40819_5	CARD|gb|ABD30512.1|ARO:3000839|arlS	26.3	358	419	451	5.32e-34	130
k141_40819_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.3	278	419	370	7.64e-29	115
k141_21262_1	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	37.7	69	70	380	3.26e-10	52.8
k141_21262_1	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	37.7	69	70	380	3.26e-10	52.8
k141_21262_1	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.9	72	70	354	6.68e-08	46.2
k141_21262_1	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.0	71	70	354	2.34e-07	44.7
k141_21262_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	40.4	57	70	370	6.03e-07	43.5
k141_21262_1	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.0	71	70	352	1.13e-06	42.7
k141_21262_1	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.0	71	70	376	1.13e-06	42.7
k141_21262_1	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	31.0	71	70	376	1.13e-06	42.7
k141_21262_1	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	37.5	56	70	381	2.90e-06	41.6
k141_21262_1	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	37.5	56	70	381	2.90e-06	41.6
k141_26630_11	SARG|gi|445996722|ref|WP_000074577.1|	32.3	220	291	309	1.68e-24	99.4
k141_26630_11	SARG|gi|445996723|ref|WP_000074578.1|	31.8	220	291	309	2.33e-24	99.0
k141_26630_11	SARG|gi|884875933|emb|CKG93789.1|	31.8	220	291	309	3.22e-24	98.6
k141_26630_11	SARG|gi|445996719|ref|WP_000074574.1|	31.4	220	291	309	4.46e-24	98.2
k141_26630_11	SARG|gi|445996724|ref|WP_000074579.1|	31.8	220	291	309	4.46e-24	98.2
k141_26630_11	SARG|gi|445996729|ref|WP_000074584.1|	31.4	220	291	309	6.17e-24	97.8
k141_26630_11	SARG|gi|1043490477|ref|WP_065382463.1|	31.4	220	291	309	6.17e-24	97.8
k141_26630_11	SARG|gi|445996726|ref|WP_000074581.1|	31.4	220	291	309	6.17e-24	97.8
k141_26630_11	SARG|gi|507054395|ref|WP_016125339.1|	31.4	220	291	309	6.17e-24	97.8
k141_26630_11	SARG|gi|445996709|ref|WP_000074564.1|	31.4	220	291	309	8.54e-24	97.4
k141_26630_12	SARG|gb|AAA26793|ARO:3003748|oleC	32.4	213	282	325	9.26e-25	100
k141_26630_12	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	32.4	213	282	325	9.26e-25	100
k141_26630_12	SARG|gi|748767925|ref|WP_040019608.1|	30.9	223	282	623	2.63e-21	92.4
k141_26630_12	SARG|gi|517381192|ref|WP_018555350.1|	29.4	221	282	602	3.49e-21	92.0
k141_26630_12	SARG|gi|860594225|ref|WP_048475168.1|	31.4	220	282	620	3.55e-21	92.0
k141_26630_12	SARG|gi|496018010|ref|WP_008742581.1|	29.0	221	282	623	3.56e-21	92.0
k141_26630_12	SARG|gi|944152509|ref|WP_055644808.1|	29.9	221	282	616	6.46e-21	91.3
k141_26630_12	SARG|gi|655401130|ref|WP_028800283.1|	30.0	217	282	599	1.16e-20	90.5
k141_26630_12	SARG|gi|664352659|ref|WP_030880307.1|	28.5	221	282	601	1.16e-20	90.5
k141_26630_12	SARG|gi|664100597|ref|WP_030638327.1|	28.5	221	282	601	1.16e-20	90.5
k141_40884_2	SARG|gi|542061059|gb|ERI11611.1|	28.0	225	288	316	1.76e-24	99.4
k141_40884_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	26.1	222	288	307	2.75e-22	93.2
k141_40884_2	SARG|gi|895808656|emb|COR83787.1|	28.0	207	288	309	1.03e-21	91.7
k141_40884_2	SARG|gi|895736250|emb|COF64653.1|	27.9	204	288	309	2.69e-21	90.5
k141_40884_2	SARG|gi|446110087|ref|WP_000187942.1|	27.9	204	288	309	2.69e-21	90.5
k141_40884_2	SARG|gi|445996714|ref|WP_000074569.1|	27.9	204	288	309	3.71e-21	90.1
k141_40884_2	SARG|gi|445996729|ref|WP_000074584.1|	27.5	207	288	309	5.11e-21	89.7
k141_40884_2	SARG|gi|445996710|ref|WP_000074565.1|	27.9	204	288	309	5.11e-21	89.7
k141_40884_2	SARG|gi|814314593|emb|CKF49145.1|	27.9	204	288	309	7.04e-21	89.4
k141_40884_2	SARG|gi|445996709|ref|WP_000074564.1|	27.9	204	288	309	1.34e-20	88.6
k141_38607_1	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	62.9	159	160	159	4.26e-65	195
k141_38646_1	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	44.2	129	132	585	1.48e-32	119
k141_38646_1	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	44.2	129	132	585	1.48e-32	119
k141_38646_1	CARD|gb|ABU39979.1|ARO:3000217|blaR1	47.2	106	132	588	4.91e-31	114
k141_38646_1	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	46.0	126	132	593	1.29e-30	113
k141_38646_1	NCBI|WP_001096386.1|1|1|blaR1-2|blaR1-2|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	37.3	126	132	585	1.83e-22	90.5
k141_38646_1	NCBI|WP_063842869.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	37.3	126	132	585	2.50e-22	90.1
k141_38646_1	NCBI|WP_001096376.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	37.3	126	132	585	2.50e-22	90.1
k141_38646_1	NCBI|WP_001096392.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	37.3	126	132	585	3.41e-22	89.7
k141_38646_1	SARG|AY227054.1.gene1.p01	35.9	128	132	254	2.94e-21	84.7
k141_38646_1	megares|MEG_4741|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	35.9	128	132	261	3.28e-21	84.7
k141_38654_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.8	223	229	232	7.87e-63	194
k141_38654_3	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.5	226	229	231	2.59e-58	183
k141_38654_3	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.5	226	229	231	7.35e-58	182
k141_38654_3	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.2	226	229	231	1.47e-57	181
k141_38654_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.4	226	229	232	1.22e-56	179
k141_38654_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.4	226	229	232	1.22e-56	179
k141_38654_3	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.7	226	229	231	9.51e-56	176
k141_38654_3	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.7	226	229	231	9.51e-56	176
k141_38654_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.2	227	229	233	1.62e-54	173
k141_38654_3	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	37.5	224	229	231	3.06e-54	172
k141_38654_4	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.5	159	181	367	1.62e-10	57.8
k141_38654_4	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	24.5	159	181	368	1.62e-10	57.8
k141_38654_4	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.6	164	181	381	7.60e-10	55.8
k141_38654_4	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.6	164	181	381	7.60e-10	55.8
k141_38654_4	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	146	181	381	1.03e-09	55.5
k141_38654_4	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	146	181	381	1.03e-09	55.5
k141_38654_4	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	146	181	381	2.57e-09	54.3
k141_38654_4	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	146	181	381	2.57e-09	54.3
k141_38654_4	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.6	87	181	380	8.65e-09	52.8
k141_38654_4	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.6	87	181	380	8.65e-09	52.8
k141_38687_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.4	112	502	231	4.34e-10	58.9
k141_38687_4	CARD|gb|ADM92605.1|ARO:3000553|adeR	24.6	138	502	247	5.26e-10	58.9
k141_38687_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	30.4	115	502	232	4.77e-09	55.8
k141_38687_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	29.6	115	502	232	1.16e-08	54.7
k141_38687_4	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.1	133	502	1197	1.32e-08	56.6
k141_38687_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.9	111	502	219	5.97e-08	52.4
k141_38687_4	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.6	108	502	231	4.01e-07	50.1
k141_38687_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	24.8	113	502	228	7.03e-07	49.3
k141_38687_4	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.2	109	502	231	1.30e-06	48.5
k141_38687_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	25.2	111	502	232	1.32e-06	48.5
k141_18779_3	SARG|gi|403023847|gb|EJY36064.1|	39.1	184	264	200	9.16e-37	128
k141_18779_3	SARG|gi|452996227|gb|AGG19410.1|	39.1	184	264	252	3.56e-36	128
k141_18779_3	SARG|gi|403219412|emb|CCJ27774.1|	39.7	184	264	268	3.73e-36	128
k141_18779_3	SARG|gi|488259314|ref|WP_002330522.1|	39.1	184	264	268	5.24e-36	128
k141_18779_3	SARG|gi|1036536100|emb|SAM71699.1|	39.1	184	264	268	5.24e-36	128
k141_18779_3	SARG|KF823969.1.gene3.p01	39.1	184	264	268	5.24e-36	128
k141_18779_3	SARG|Q47746	39.1	184	264	268	1.45e-35	127
k141_18779_3	SARG|gi|452996213|gb|AGG19398.1|	39.1	184	264	268	1.45e-35	127
k141_18779_3	SARG|gi|498515090|ref|WP_010815297.1|	39.1	184	264	268	1.45e-35	127
k141_18779_3	NCBI|WP_063856820.1|1|1|vanXY-N|vanXY-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-N|AMR|glycopeptide	35.3	184	264	190	2.88e-27	103
k141_18796_12	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	36.7	120	129	126	6.18e-28	98.6
k141_18796_12	NCBI|WP_000196386.1|1|1|mecI_of_mecC|mecI_of_mecC||2|METHICILLIN|beta-lactam|mecC-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	33.6	116	129	124	7.01e-24	88.2
k141_18796_13	CARD|gb|ABU39979.1|ARO:3000217|blaR1	39.1	571	599	588	5.17e-129	390
k141_18796_13	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	33.6	580	599	593	1.12e-104	327
k141_18796_13	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	32.0	584	599	585	2.09e-98	310
k141_18796_13	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	32.0	584	599	585	2.09e-98	310
k141_18796_13	NCBI|WP_063842869.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	29.9	586	599	585	1.23e-80	264
k141_18796_13	NCBI|WP_001096376.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	29.9	586	599	585	1.72e-80	263
k141_18796_13	NCBI|WP_001096392.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	29.0	586	599	585	3.51e-79	260
k141_18796_13	NCBI|WP_001096386.1|1|1|blaR1-2|blaR1-2|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	29.8	604	599	585	4.91e-79	259
k141_18796_13	NCBI|WP_075071939.1|1|1|blaOXA-1089|blaOXA-1089_fam|hydrolase|2|CARBAPENEM|beta-lactam|carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-1089|AMR|beta-lactam	40.9	232	599	289	3.54e-48	169
k141_18796_13	SARG|gb|EIM09515.1|ARO:3004747|BAT-1	35.6	239	599	268	1.42e-47	166
k141_12976_2	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	41.0	522	510	533	5.27e-100	310
k141_12976_2	SARG|AF353562.gene.p01	36.4	363	510	369	1.04e-53	184
k141_35376_1	SARG|gb|CAL84423.1|ARO:3004146|cfrC	38.4	320	349	344	9.50e-64	205
k141_35376_1	SARG|CP001581.1.gene3143.p01	38.1	323	349	344	2.66e-63	204
k141_35376_1	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	39.0	328	349	416	6.25e-59	194
k141_35376_1	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	36.9	331	349	349	8.85e-59	192
k141_35376_1	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	38.4	328	349	379	1.37e-58	192
k141_35376_1	SARG|AJ249217.gene.p01	36.9	331	349	349	2.47e-58	191
k141_35376_1	SARG|gb|BAD63613.1|ARO:3002816|clbC	37.1	350	349	350	9.95e-58	189
k141_35376_1	SARG|AXY65402.1	36.5	342	349	357	2.36e-57	189
k141_35376_1	SARG|VXQ21601.1	38.3	266	349	344	3.06e-54	180
k141_1988_4	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.2	241	306	258	4.51e-36	129
k141_1988_4	SARG|gi|895865878|ref|WP_048974758.1|	34.1	220	306	646	6.21e-26	106
k141_1988_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.5	217	306	664	6.51e-20	89.0
k141_1988_4	SARG|gb|CDO61516.1|ARO:3003949|efrB	30.9	204	306	362	3.49e-18	82.8
k141_1988_4	SARG|gb|AAK76136.1|ARO:3000025|patB	27.6	217	306	588	9.70e-18	82.4
k141_1988_4	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	30.1	219	306	579	3.39e-16	77.8
k141_1988_4	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.8	222	306	579	8.24e-16	76.6
k141_1988_4	SARG|M80346.gene.p01	23.3	258	306	551	6.69e-14	70.9
k141_1988_4	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	23.3	249	306	551	1.61e-13	69.7
k141_7174_3	megares|MEG_3790|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	35.1	644	705	666	4.39e-119	370
k141_7174_3	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	34.1	696	705	665	1.67e-118	369
k141_7174_3	SARG|gb|CCC86795.1|ARO:3001209|mecC	34.4	655	705	665	3.30e-118	368
k141_7174_3	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	34.8	655	705	664	1.25e-117	366
k141_7174_3	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	35.0	655	705	665	3.58e-117	365
k141_7174_3	SARG|gi|814562231|ref|WP_046377063.1|	35.2	647	705	668	3.88e-117	365
k141_7174_3	SARG|gi|686288520|ref|WP_031860875.1|	35.1	647	705	668	7.66e-117	364
k141_7174_3	SARG|gi|2791908|emb|CAA73538.1|	35.1	644	705	666	1.02e-116	364
k141_7174_3	SARG|gi|909708119|ref|WP_049951317.1|	35.1	647	705	649	1.26e-116	363
k141_7174_3	SARG|gi|486697816|ref|WP_001620256.1|	35.1	647	705	668	1.51e-116	363
k141_16119_2	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	228	331	381	3.30e-23	97.8
k141_16119_2	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	228	331	381	3.30e-23	97.8
k141_16119_2	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.3	297	331	361	1.28e-22	95.9
k141_16119_2	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	228	331	381	4.05e-22	94.7
k141_16119_2	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	228	331	381	4.05e-22	94.7
k141_16119_2	SARG|gb|AAG05187.1|ARO:3005067|ParS	26.9	253	331	428	1.10e-21	94.0
k141_16119_2	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	227	331	381	9.08e-21	90.9
k141_16119_2	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	227	331	381	9.08e-21	90.9
k141_16119_2	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.2	226	331	381	1.24e-20	90.5
k141_16119_2	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.2	226	331	381	1.24e-20	90.5
k141_26785_7	SARG|gi|500194536|ref|WP_011867743.1|	29.1	237	229	306	5.22e-22	90.9
k141_26785_7	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	27.6	185	229	505	4.34e-11	60.8
k141_26785_7	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	27.3	172	229	494	1.92e-10	58.9
k141_26785_7	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	26.9	186	229	504	1.16e-09	56.6
k141_26785_7	SARG|AXF35727.1	27.1	177	229	497	2.09e-09	55.8
k141_26785_7	SARG|gi|488338532|ref|WP_002407917.1|	24.3	210	229	498	3.80e-09	55.1
k141_26785_7	ResF|poxtA-Ef_1_WP094899500.1_1	28.4	155	229	538	7.08e-09	54.3
k141_26785_7	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	28.4	155	229	543	7.10e-09	54.3
k141_26785_7	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	28.4	155	229	543	7.10e-09	54.3
k141_26785_7	SARG|U82085.gene.p01	27.3	183	229	552	1.85e-07	50.1
k141_41223_2	ResF|penA_1_AF515059_1	23.5	417	463	581	3.42e-12	67.4
k141_16212_13	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	49.6	230	233	233	5.53e-77	231
k141_16212_13	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	48.9	229	233	231	5.96e-76	228
k141_16212_13	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	48.9	229	233	231	5.96e-76	228
k141_16212_13	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	48.5	231	233	235	1.36e-75	227
k141_16212_13	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	49.6	232	233	239	8.87e-75	225
k141_16212_13	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	47.4	230	233	232	8.15e-74	223
k141_16212_13	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	47.4	230	233	232	8.15e-74	223
k141_16212_13	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	48.5	227	233	231	7.35e-72	218
k141_16212_13	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	48.5	227	233	231	1.04e-71	217
k141_16212_13	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	48.5	227	233	231	1.04e-71	217
k141_16212_14	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.1	306	728	381	1.93e-37	143
k141_16212_14	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.1	306	728	381	1.93e-37	143
k141_16212_14	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.1	306	728	381	8.98e-37	141
k141_16212_14	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.1	306	728	381	8.98e-37	141
k141_16212_14	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	306	728	381	1.66e-36	140
k141_16212_14	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	306	728	381	1.66e-36	140
k141_16212_14	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.6	304	728	381	9.51e-32	126
k141_16212_14	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.6	304	728	381	9.51e-32	126
k141_16212_14	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.9	266	728	380	3.48e-30	122
k141_16212_14	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.9	266	728	380	3.48e-30	122
k141_16212_20	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	31.0	510	592	579	3.60e-69	233
k141_16212_20	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.6	518	592	582	3.91e-68	230
k141_16212_20	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.4	516	592	579	7.21e-67	227
k141_16212_20	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.8	509	592	664	2.16e-58	206
k141_16212_20	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	31.2	401	592	574	3.28e-58	203
k141_16212_20	SARG|gb|AAK76136.1|ARO:3000025|patB	29.9	531	592	588	3.99e-56	198
k141_16212_20	SARG|gi|505420018|ref|WP_015607120.1|	27.2	526	592	603	3.41e-54	193
k141_16212_20	SARG|gi|664180077|ref|WP_030714054.1|	28.0	493	592	605	4.86e-54	192
k141_16212_20	SARG|gi|1045390184|ref|WP_065479071.1|	27.8	493	592	605	6.71e-54	192
k141_16212_20	SARG|gi|930482089|ref|WP_054228897.1|	40.9	235	592	599	8.40e-54	192
k141_10283_5	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.0	243	259	664	3.46e-14	70.9
k141_7353_1	SARG|AAA50325	42.9	49	154	569	3.18e-06	44.7
k141_18999_2	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	34.3	201	243	310	1.30e-31	117
k141_26896_13	SARG|gb|CAE00499.1|ARO:3003835|cdeA	28.3	434	459	441	5.25e-51	177
k141_26896_13	SARG|HE999704.1.gene3064.p01	34.2	199	459	241	5.20e-29	113
k141_16364_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	46.0	226	312	232	8.68e-65	202
k141_16364_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.0	230	312	231	3.45e-55	178
k141_16364_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	40.1	227	312	229	1.57e-49	163
k141_16364_2	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.4	238	312	239	1.56e-45	153
k141_16364_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	28.4	229	312	223	9.24e-27	103
k141_16364_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.4	296	351	370	5.39e-14	71.2
k141_16364_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.7	232	351	365	4.14e-13	68.6
k141_19044_4	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.3	219	223	225	1.56e-39	134
k141_19044_4	CARD|gb|AAC73788.1|ARO:3003841|kdpE	33.3	219	223	225	1.56e-39	134
k141_19044_4	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.1	219	223	220	1.20e-37	129
k141_19044_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	30.0	223	223	229	2.60e-35	124
k141_19044_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	28.9	228	223	239	1.70e-31	114
k141_19044_4	CARD|gb|AAD51348.1|ARO:3003066|smeR	33.0	215	223	229	7.38e-31	112
k141_19044_4	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	27.0	226	223	223	1.70e-26	100
k141_19044_4	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.0	220	223	223	1.82e-25	98.2
k141_19044_6	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.3	218	224	255	6.63e-52	167
k141_19044_6	SARG|gi|896325272|ref|WP_049294291.1|	43.7	213	224	648	1.93e-50	172
k141_19044_6	SARG|gi|639225329|ref|WP_024561799.1|	43.4	212	224	648	2.68e-50	172
k141_19044_6	SARG|gi|639218559|ref|WP_024556062.1|	43.4	212	224	648	2.68e-50	172
k141_19044_6	SARG|gi|657888313|ref|WP_029592374.1|	42.9	212	224	648	3.72e-50	171
k141_19044_6	SARG|gi|639216333|ref|WP_024554080.1|	43.2	213	224	648	5.16e-50	171
k141_19044_6	SARG|gi|754927849|ref|WP_042284850.1|	41.7	218	224	648	5.16e-50	171
k141_19044_6	SARG|gi|506220920|ref|WP_015740695.1|	44.8	212	224	647	7.09e-50	171
k141_19044_6	SARG|gi|992390012|ref|WP_061077002.1|	41.7	218	224	648	9.94e-50	170
k141_19044_6	SARG|Q83LR7	42.9	212	224	648	1.38e-49	170
k141_13195_5	SARG|YP_302230	21.7	300	461	451	5.23e-08	53.9
k141_13195_5	SARG|gi|488374619|ref|WP_002444004.1|	21.7	300	461	452	6.15e-06	47.4
k141_13195_9	SARG|gb|WP_096809342.1|ARO:3007029|salE	24.6	187	251	543	2.25e-09	56.2
k141_41434_2	CARD|gb|WKR28567.1|ARO:3007678|IreK	35.4	684	698	718	8.17e-95	308
k141_41434_12	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.4	211	299	255	1.03e-22	93.6
k141_41434_12	SARG|gi|1033064422|ref|WP_064375412.1|	27.6	239	299	648	1.03e-19	88.2
k141_41434_12	SARG|gi|498115003|ref|WP_010429159.1|	27.9	233	299	646	4.58e-19	86.3
k141_41434_12	SARG|gi|502669352|ref|WP_012905216.1|	27.0	233	299	648	8.34e-19	85.5
k141_41434_12	SARG|gi|960873409|ref|WP_058345546.1|	26.7	243	299	648	8.34e-19	85.5
k141_41434_12	SARG|gi|803568669|ref|WP_046077412.1|	27.7	231	299	648	1.12e-18	85.1
k141_41434_12	SARG|gi|446110352|ref|WP_000188207.1|	27.7	231	299	648	1.12e-18	85.1
k141_41434_12	SARG|YP_002382193	27.7	231	299	648	1.12e-18	85.1
k141_41434_12	SARG|gi|803575554|ref|WP_046081557.1|	27.7	231	299	648	1.12e-18	85.1
k141_41434_12	SARG|gi|817104523|ref|WP_046477871.1|	26.2	233	299	648	1.12e-18	85.1
k141_4809_5	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	29.1	261	292	243	9.45e-20	85.1
k141_4809_5	SARG|L22689.1.gene1.p01	29.2	236	292	257	1.20e-19	85.1
k141_4809_5	SARG|gb|QQM99828.1|ARO:3007041|Erm(52)	29.9	187	292	309	2.31e-18	82.4
k141_4809_5	SARG|gi|488250641|ref|WP_002321849.1|	28.9	239	292	245	4.69e-18	80.5
k141_4809_5	SARG|gi|695273519|ref|WP_032495453.1|	30.3	188	292	245	6.46e-18	80.1
k141_4809_5	NCBI|WP_063844598.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	28.9	239	292	245	6.46e-18	80.1
k141_4809_5	megares|MEG_2801|Drugs|MLS|23S_rRNA_methyltransferases|ERMB_1	28.9	239	292	253	7.33e-18	80.1
k141_4809_5	NCBI|WP_001038790.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	28.9	239	292	245	8.90e-18	79.7
k141_4809_5	NCBI|WP_063844601.1|1|1|erm(B)|erm(B)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN/STREPTOGRAMIN_B|LINCOSAMIDE/MACROLIDE/STREPTOGRAMIN|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(B)|AMR|multidrug	28.5	239	292	245	1.69e-17	79.0
k141_4809_5	SARG|gi|494752321|ref|WP_007487729.1|	28.5	239	292	245	1.69e-17	79.0
k141_4846_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	45.0	220	222	255	9.97e-62	192
k141_4846_2	SARG|gi|1001720867|ref|WP_061274204.1|	42.5	221	222	648	4.87e-52	176
k141_4846_2	SARG|gi|1035706844|ref|WP_064548272.1|	42.5	221	222	648	6.77e-52	176
k141_4846_2	SARG|gi|736472622|ref|WP_034494292.1|	42.1	221	222	648	1.81e-51	175
k141_4846_2	SARG|gi|495736522|ref|WP_008461101.1|	42.1	221	222	648	2.52e-51	174
k141_4846_2	SARG|gi|746253210|ref|WP_039301529.1|	42.1	221	222	648	2.52e-51	174
k141_4846_2	SARG|gi|1035670474|ref|WP_064517458.1|	41.6	221	222	648	4.86e-51	174
k141_4846_2	SARG|gi|1035717981|ref|WP_064557480.1|	41.6	221	222	648	4.86e-51	174
k141_4846_2	SARG|gi|746243059|ref|WP_039291473.1|	42.1	221	222	648	6.74e-51	173
k141_4846_2	SARG|gi|1033064422|ref|WP_064375412.1|	40.7	221	222	648	1.80e-50	172
k141_4846_3	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.1	217	344	885	2.32e-14	73.2
k141_4846_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	32.0	228	230	232	2.28e-32	116
k141_4846_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	32.0	228	230	232	2.28e-32	116
k141_4846_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	31.0	232	230	235	1.46e-30	112
k141_4846_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.9	223	230	228	6.76e-30	110
k141_4846_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	31.3	233	230	239	1.23e-29	109
k141_4846_4	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	221	230	219	2.13e-29	108
k141_4846_4	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	221	230	219	2.99e-29	108
k141_4846_4	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	221	230	220	3.06e-29	108
k141_4846_4	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	221	230	220	4.30e-29	107
k141_4846_4	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.0	230	230	231	1.54e-28	106
k141_4882_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.7	287	401	370	1.45e-12	67.4
k141_4882_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.0	282	401	365	8.10e-11	62.0
k141_4882_3	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.6	217	401	381	3.40e-07	50.8
k141_4882_3	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.6	217	401	381	3.40e-07	50.8
k141_4882_3	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.8	219	401	381	5.99e-07	50.1
k141_4882_3	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.8	219	401	381	5.99e-07	50.1
k141_4882_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	46.7	122	141	231	8.67e-31	109
k141_4882_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.7	122	141	231	8.67e-31	109
k141_4882_4	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.6	136	141	231	2.43e-30	108
k141_4882_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.5	123	141	231	3.43e-30	107
k141_4882_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.5	119	141	232	1.95e-29	105
k141_4882_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.5	119	141	232	1.95e-29	105
k141_4882_4	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.2	136	141	229	3.62e-29	105
k141_4882_4	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.7	123	141	231	3.79e-29	105
k141_4882_4	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.6	133	141	232	8.46e-28	101
k141_4882_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.8	121	141	231	1.17e-27	101
k141_35720_6	megares|MEG_727|Drugs|beta-lactam|Class_C_betalactamases|AMPC_1	40.2	398	411	415	1.22e-103	312
k141_5062_22	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.0	491	519	655	1.20e-89	287
k141_5062_22	SARG|gb|AKA86814|ARO:3003746|optrA	33.0	491	519	655	1.20e-89	287
k141_5062_22	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.0	491	519	655	3.30e-89	286
k141_5062_22	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.0	491	519	655	3.30e-89	286
k141_5062_22	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.0	491	519	655	3.30e-89	286
k141_5062_22	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.0	491	519	655	4.63e-89	285
k141_5062_22	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.0	491	519	655	6.49e-89	285
k141_5062_22	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.8	491	519	655	1.28e-88	284
k141_5062_22	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.8	491	519	655	2.51e-88	283
k141_5062_22	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.8	491	519	655	2.51e-88	283
k141_16808_11	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	45.0	231	231	232	9.15e-65	199
k141_16808_11	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.0	225	231	231	2.52e-64	198
k141_16808_11	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.6	231	231	232	2.60e-64	198
k141_16808_11	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	45.1	226	231	232	5.22e-64	197
k141_16808_11	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.7	232	231	233	1.13e-60	189
k141_16808_11	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.6	230	231	231	1.51e-60	189
k141_16808_11	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	42.2	230	231	231	4.29e-60	187
k141_16808_11	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.0	230	231	231	6.07e-60	187
k141_16808_11	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.2	230	231	231	4.89e-59	185
k141_16808_11	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	43.1	232	231	239	8.81e-59	184
k141_16808_12	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	33.2	226	352	384	1.03e-27	110
k141_16808_12	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	33.2	226	352	384	1.03e-27	110
k141_16808_12	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	30.1	279	352	386	1.87e-26	107
k141_16808_12	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	32.7	226	352	386	1.87e-26	107
k141_16808_12	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	30.1	279	352	386	1.87e-26	107
k141_16808_12	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	32.7	226	352	386	1.87e-26	107
k141_16808_12	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	30.1	279	352	388	1.28e-25	105
k141_16808_12	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	30.1	279	352	388	1.28e-25	105
k141_16808_12	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	22.4	326	352	370	9.42e-25	102
k141_16808_12	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.3	297	352	359	7.50e-24	99.8
k141_44320_6	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	32.8	189	683	722	3.20e-20	94.4
k141_44320_8	SARG|gb|CAE00499.1|ARO:3003835|cdeA	29.3	426	441	441	2.10e-62	207
k141_19275_2	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	44.9	1036	1052	1033	0.0	930
k141_19275_2	SARG|gb|AEY83581|ARO:3000510|mupB	44.9	1036	1052	1033	0.0	930
k141_19275_2	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	45.5	996	1052	1024	0.0	922
k141_19275_2	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	45.5	996	1052	1024	0.0	922
k141_19275_2	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	45.3	996	1052	1024	0.0	916
k141_19275_2	SARG|gb|CAA53189|ARO:3000521|mupA	45.3	996	1052	1024	0.0	916
k141_19275_2	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	37.2	1071	1052	1107	7.99e-226	672
k141_19275_2	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	37.2	1071	1052	1107	7.99e-226	672
k141_2424_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	500	506	655	5.63e-68	229
k141_2424_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	30.6	517	506	648	6.89e-68	229
k141_2424_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	500	506	655	7.84e-68	229
k141_2424_1	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	500	506	655	7.84e-68	229
k141_2424_1	SARG|gb|AKA86814|ARO:3003746|optrA	29.6	500	506	655	7.84e-68	229
k141_2424_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	500	506	655	2.12e-67	228
k141_2424_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	500	506	655	2.12e-67	228
k141_2424_1	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	500	506	655	2.12e-67	228
k141_2424_1	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	500	506	655	2.12e-67	228
k141_2424_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	500	506	655	2.95e-67	227
k141_2479_3	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	50.9	55	199	293	9.55e-13	64.3
k141_2479_3	SARG|gi|446048013|ref|WP_000125868.1|	56.9	51	199	648	3.58e-08	51.6
k141_2479_3	SARG|gb|AEA37904.1|ARO:3003112|lsaC	49.1	53	199	492	4.50e-08	51.2
k141_2479_3	SARG|gb|AAK76137.1|ARO:3000024|patA	47.9	48	199	564	1.15e-07	50.1
k141_22108_8	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	22.4	219	279	522	7.74e-08	52.0
k141_22108_8	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	22.4	219	279	522	1.38e-07	51.2
k141_22108_8	SARG|DQ823382.1.gene1.p01	22.4	219	279	522	1.38e-07	51.2
k141_22108_8	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	22.4	219	279	522	1.38e-07	51.2
k141_22108_8	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	22.4	219	279	522	1.38e-07	51.2
k141_22108_8	SARG|AAF24091	22.4	219	279	522	1.38e-07	51.2
k141_22108_8	SARG|YP_002332257	22.4	219	279	522	1.38e-07	51.2
k141_22108_8	SARG|AAG08983	22.3	220	279	524	1.85e-07	50.8
k141_22108_8	SARG|gb|AEO25219.1|ARO:3004651|lin	23.1	221	279	523	2.46e-07	50.4
k141_22108_8	SARG|KC539823.1.gene1.p01	22.5	218	279	522	3.29e-07	50.1
k141_27455_1	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	24.0	204	291	346	8.71e-09	54.7
k141_22139_2	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.3	826	883	1024	3.69e-64	233
k141_22139_2	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.3	826	883	1024	3.69e-64	233
k141_22139_2	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.3	826	883	1024	6.73e-64	232
k141_22139_2	SARG|gb|CAA53189|ARO:3000521|mupA	24.3	826	883	1024	6.73e-64	232
k141_27463_1	SARG|HE999704.1.gene3064.p01	25.4	201	443	241	8.60e-17	78.6
k141_27463_1	SARG|gi|441475675|emb|CCQ25429.1|	33.1	118	443	211	2.48e-11	62.0
k141_36100_4	SARG|gi|1032819400|ref|WP_064325534.1|	26.3	179	245	646	2.15e-13	68.2
k141_36100_4	SARG|gi|654544841|ref|WP_028012549.1|	25.6	199	245	646	3.91e-13	67.4
k141_36100_4	SARG|gi|896106549|ref|WP_049136608.1|	25.6	199	245	646	3.91e-13	67.4
k141_36100_4	SARG|gi|829942568|ref|WP_047368199.1|	25.6	199	245	646	3.91e-13	67.4
k141_36100_4	SARG|gi|976150171|ref|WP_059308384.1|	25.1	199	245	646	5.28e-13	67.0
k141_36100_4	SARG|gi|895898290|ref|WP_048999361.1|	25.6	199	245	646	5.28e-13	67.0
k141_36100_4	SARG|gi|749017716|ref|WP_040076354.1|	26.1	203	245	646	5.28e-13	67.0
k141_36100_4	SARG|gi|895905590|ref|WP_049005458.1|	25.6	199	245	646	9.60e-13	66.2
k141_36100_4	SARG|gi|654551607|ref|WP_028019265.1|	25.6	199	245	646	1.29e-12	65.9
k141_36100_4	SARG|gi|695701476|ref|WP_032638992.1|	25.1	199	245	646	1.05e-11	63.2
k141_44453_11	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	24.0	204	413	346	5.86e-08	53.1
k141_7663_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.7	110	478	228	1.74e-09	57.0
k141_7663_1	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.0	104	478	204	1.68e-06	47.8
k141_7663_9	SARG|gb|CAE00499.1|ARO:3003835|cdeA	25.7	448	458	441	1.23e-38	144
k141_7663_9	SARG|ZP_04679156	27.0	403	458	451	6.35e-36	137
k141_7663_9	SARG|gi|505177635|ref|WP_015364737.1|	28.0	403	458	451	2.27e-35	135
k141_7663_9	SARG|gi|488374619|ref|WP_002444004.1|	25.5	416	458	452	3.30e-32	126
k141_7663_9	SARG|gi|1006223553|ref|WP_061745579.1|	23.7	451	458	451	1.97e-28	115
k141_7663_9	SARG|gi|686396521|ref|WP_031908504.1|	24.2	438	458	451	6.75e-28	114
k141_7663_9	SARG|gi|446573718|ref|WP_000651064.1|	27.0	389	458	451	6.75e-28	114
k141_7663_9	SARG|YP_302230	24.3	452	458	451	1.25e-27	113
k141_7663_9	SARG|ZP_03986195	24.0	438	458	451	1.69e-27	113
k141_7663_9	SARG|gi|446573695|ref|WP_000651041.1|	24.0	438	458	451	1.69e-27	113
k141_39465_2	SARG|gi|657888313|ref|WP_029592374.1|	46.4	224	225	648	2.47e-60	199
k141_39465_2	SARG|gi|851928815|ref|WP_048221086.1|	44.8	223	225	648	6.70e-60	197
k141_39465_2	SARG|gi|780033092|ref|WP_045444768.1|	44.8	223	225	648	6.70e-60	197
k141_39465_2	SARG|gi|742378414|ref|WP_038857601.1|	45.7	223	225	647	9.21e-60	197
k141_39465_2	SARG|gi|639225329|ref|WP_024561799.1|	46.0	224	225	648	9.35e-60	197
k141_39465_2	SARG|gi|639218559|ref|WP_024556062.1|	46.0	224	225	648	9.35e-60	197
k141_39465_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	42.3	222	225	255	1.43e-59	187
k141_39465_2	SARG|gi|1020141879|ref|WP_063264839.1|	45.7	223	225	647	1.79e-59	196
k141_39465_2	SARG|gi|1035670474|ref|WP_064517458.1|	45.3	223	225	648	1.82e-59	196
k141_39465_2	SARG|gi|1035717981|ref|WP_064557480.1|	45.3	223	225	648	1.82e-59	196
k141_39465_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.0	226	230	370	4.47e-23	94.7
k141_39465_3	CARD|gb|AEX49906.1|ARO:3003583|basS	26.1	226	230	477	5.32e-21	89.7
k141_36152_1	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.6	116	123	231	2.67e-16	70.9
k141_36152_1	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	36.6	93	123	230	7.37e-15	67.0
k141_36152_5	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	53.5	1240	1286	1162	0.0	1224
k141_36152_5	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	51.5	1262	1286	1186	0.0	1165
k141_36152_5	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	51.5	1262	1286	1186	0.0	1165
k141_33164_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.4	232	221	232	1.60e-46	152
k141_33164_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.4	232	221	232	1.60e-46	152
k141_33164_2	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.1	232	221	235	5.52e-45	149
k141_33164_2	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.0	231	221	232	1.01e-44	148
k141_33164_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.8	229	221	229	5.25e-44	146
k141_33164_2	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.6	234	221	232	2.27e-43	144
k141_33164_2	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.0	230	221	232	9.02e-43	143
k141_33164_2	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.0	230	221	232	1.80e-42	142
k141_33164_2	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.0	230	221	232	2.54e-42	142
k141_33164_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.0	229	221	231	3.49e-42	141
k141_33164_5	SARG|gi|507044560|ref|WP_016115614.1|	49.6	236	238	306	8.93e-71	218
k141_33164_5	SARG|gi|446026113|ref|WP_000103968.1|	49.2	236	238	306	5.07e-70	216
k141_33164_5	SARG|gi|445996719|ref|WP_000074574.1|	50.6	237	238	309	5.54e-70	216
k141_33164_5	SARG|gi|445996710|ref|WP_000074565.1|	50.6	237	238	309	5.54e-70	216
k141_33164_5	SARG|gi|488120365|ref|WP_002191762.1|	50.6	237	238	309	1.11e-69	215
k141_33164_5	SARG|gi|895736250|emb|COF64653.1|	50.6	237	238	309	1.57e-69	214
k141_33164_5	SARG|gi|446110087|ref|WP_000187942.1|	50.6	237	238	309	1.57e-69	214
k141_33164_5	SARG|gi|445996708|ref|WP_000074563.1|	50.6	237	238	309	2.22e-69	214
k141_33164_5	SARG|gi|488042066|ref|WP_002113463.1|	51.1	237	238	309	2.22e-69	214
k141_33164_5	SARG|gi|445996714|ref|WP_000074569.1|	50.6	237	238	309	2.22e-69	214
k141_19609_3	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	44.8	223	231	229	1.49e-57	181
k141_19609_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.4	226	231	231	8.96e-57	179
k141_19609_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.2	227	231	232	1.31e-56	179
k141_19609_3	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.1	227	231	231	3.59e-56	177
k141_19609_3	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.1	227	231	231	5.09e-56	177
k141_19609_3	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.1	227	231	231	1.02e-55	176
k141_19609_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.6	226	231	233	1.53e-55	176
k141_19609_3	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	43.8	226	231	230	1.98e-55	176
k141_19609_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.0	224	231	232	4.21e-55	175
k141_19609_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.0	224	231	232	4.21e-55	175
k141_11110_6	SARG|gi|446048013|ref|WP_000125868.1|	29.1	223	499	648	6.50e-22	98.2
k141_11110_6	SARG|P42332	28.0	214	499	306	3.42e-20	90.1
k141_11110_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.0	214	499	306	3.42e-20	90.1
k141_11110_6	SARG|gi|510143239|gb|AGN36970.1|	28.0	214	499	313	3.78e-20	90.1
k141_11110_6	SARG|ABB80128	28.0	214	499	306	6.25e-20	89.4
k141_11110_6	SARG|AAD21213	28.0	214	499	306	1.14e-19	88.6
k141_11110_6	SARG|YP_001373621	27.1	214	499	318	6.06e-19	86.7
k141_11110_6	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	29.2	219	499	293	6.44e-18	83.2
k141_11110_6	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.4	209	499	664	1.10e-12	69.3
k141_11110_6	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.4	213	499	575	3.03e-12	67.8
k141_2815_1	SARG|ACF08831	37.5	128	398	639	1.46e-16	80.5
k141_2815_1	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.5	128	398	639	1.10e-15	77.8
k141_2815_2	SARG|NP_348076	28.1	679	706	652	2.54e-74	251
k141_2815_2	SARG|L42544.gene.p01	26.9	683	706	651	1.28e-72	247
k141_2815_2	SARG|AAV80410	26.9	683	706	651	2.45e-72	246
k141_2815_2	SARG|YP_002850805	27.4	679	706	652	4.67e-70	240
k141_2815_2	SARG|ZP_02952732	27.1	679	706	652	4.57e-69	237
k141_2815_2	SARG|ZP_02632674	27.1	679	706	660	5.33e-69	237
k141_2815_2	SARG|L20800.gene.p01	27.1	679	706	652	1.68e-68	236
k141_2815_2	SARG|AJ514254.gene.p01	26.8	695	706	640	4.46e-65	226
k141_2815_2	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	28.1	672	706	639	1.53e-63	222
k141_2815_2	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.6	671	706	629	1.60e-61	216
k141_7982_4	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.0	211	291	578	2.28e-14	72.0
k141_7982_4	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.6	207	291	574	9.98e-14	70.1
k141_39661_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	43.2	227	224	255	1.57e-58	184
k141_39661_2	SARG|gi|498115003|ref|WP_010429159.1|	40.6	224	224	646	1.31e-47	164
k141_39661_2	SARG|Q83LR7	40.7	221	224	648	1.33e-47	164
k141_39661_2	SARG|gi|647325472|ref|WP_025760953.1|	40.7	221	224	648	1.33e-47	164
k141_39661_2	SARG|gi|647323678|ref|WP_025760497.1|	40.7	221	224	648	1.33e-47	164
k141_39661_2	SARG|gi|507086196|ref|WP_016156937.1|	38.1	223	224	648	2.55e-47	164
k141_39661_2	SARG|gi|736472622|ref|WP_034494292.1|	39.6	225	224	648	2.55e-47	164
k141_39661_2	SARG|gi|896106549|ref|WP_049136608.1|	40.6	224	224	646	3.47e-47	163
k141_39661_2	SARG|gi|654544841|ref|WP_028012549.1|	40.2	224	224	646	4.80e-47	163
k141_39661_2	SARG|gi|749639729|ref|WP_040241690.1|	38.6	223	224	646	4.80e-47	163
k141_30496_7	SARG|gi|749017716|ref|WP_040076354.1|	30.1	229	518	646	1.79e-22	100
k141_30496_7	SARG|gi|949731360|ref|WP_057072003.1|	31.3	224	518	646	4.22e-22	99.0
k141_30496_7	SARG|gi|829942568|ref|WP_047368199.1|	31.7	224	518	646	1.32e-21	97.4
k141_30496_7	SARG|gi|654544841|ref|WP_028012549.1|	31.7	224	518	646	1.76e-21	97.1
k141_30496_7	SARG|YP_001176128	29.9	234	518	646	1.76e-21	97.1
k141_30496_7	SARG|gi|896106549|ref|WP_049136608.1|	31.3	224	518	646	2.34e-21	96.7
k141_30496_7	SARG|gi|974588181|ref|WP_059178476.1|	30.8	224	518	646	3.11e-21	96.3
k141_30496_7	SARG|gi|1022698495|ref|WP_063449190.1|	30.3	234	518	646	7.32e-21	95.1
k141_30496_7	SARG|gi|1015876944|ref|WP_062856780.1|	30.8	224	518	646	7.32e-21	95.1
k141_30496_7	SARG|gi|754493745|ref|WP_041910640.1|	31.3	224	518	646	9.74e-21	94.7
k141_41924_9	CARD|gb|BAB36671.1|ARO:3000832|evgA	24.8	105	335	204	6.08e-06	45.4
k141_27959_6	SARG|gi|446048013|ref|WP_000125868.1|	27.4	226	511	648	4.82e-18	86.3
k141_27959_6	SARG|gb|AAC75271.1|ARO:3003952|yojI	31.0	197	511	547	1.10e-14	75.5
k141_27959_6	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	25.9	201	511	578	3.59e-14	73.9
k141_27959_6	SARG|gb|AYV52072.1|ARO:3002882|lmrD	25.1	203	511	664	7.56e-11	63.5
k141_44938_7	SARG|gb|APB03216.1|ARO:3003982|LlmA	61.3	287	288	287	2.27e-134	380
k141_36576_1	SARG|gi|516574297|ref|WP_017949361.1|	32.0	485	514	620	3.63e-67	226
k141_36576_1	SARG|gi|664556405|ref|WP_031071225.1|	30.4	494	514	602	1.87e-66	224
k141_36576_1	SARG|gi|497748188|ref|WP_010062372.1|	29.9	536	514	605	5.37e-66	223
k141_36576_1	SARG|gi|860594225|ref|WP_048475168.1|	29.4	524	514	620	1.39e-65	222
k141_36576_1	SARG|gi|944152509|ref|WP_055644808.1|	29.9	528	514	616	1.79e-65	222
k141_36576_1	SARG|gi|1045390184|ref|WP_065479071.1|	28.8	528	514	605	2.02e-65	221
k141_36576_1	SARG|gi|516795764|ref|WP_018105258.1|	29.9	499	514	601	3.63e-65	221
k141_36576_1	SARG|gi|917172177|ref|WP_051778889.1|	30.6	533	514	620	3.75e-65	221
k141_36576_1	SARG|gi|921231571|ref|WP_053176464.1|	30.6	533	514	620	3.75e-65	221
k141_36576_1	SARG|gi|505420018|ref|WP_015607120.1|	29.2	483	514	603	3.78e-65	221
k141_42187_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.7	112	261	228	3.90e-08	51.6
k141_42187_2	CARD|gb|BAB36671.1|ARO:3000832|evgA	31.8	85	261	204	1.93e-07	49.3
k141_33792_3	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.5	131	235	219	7.92e-07	47.4
k141_33792_3	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.5	131	235	219	7.92e-07	47.4
k141_33792_3	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.5	131	235	220	7.98e-07	47.4
k141_33792_3	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.5	131	235	220	1.08e-06	47.0
k141_33792_3	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.7	130	235	220	1.08e-06	47.0
k141_33792_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.8	91	235	219	1.45e-06	46.6
k141_33792_3	CARD|gb|AAG06465.1|ARO:3005063|cprR	26.9	93	235	223	3.68e-06	45.4
k141_33792_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.9	107	235	228	9.34e-06	44.3
k141_28134_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.2	54	89	664	1.42e-07	46.2
k141_28134_1	SARG|gb|AAK76136.1|ARO:3000025|patB	35.2	54	89	588	9.17e-07	43.9
k141_28134_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	40.0	45	89	362	1.20e-06	43.5
k141_28134_1	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	27.8	79	89	578	8.18e-06	41.2
k141_36854_3	CARD|gb|CYF42523.1|ARO:3004047|kdpD	47.4	57	86	885	2.04e-11	57.0
k141_33907_4	SARG|gi|498115003|ref|WP_010429159.1|	37.6	221	229	646	3.21e-41	147
k141_33907_4	SARG|gi|851931792|ref|WP_048222288.1|	37.6	221	229	646	6.10e-41	146
k141_33907_4	SARG|gi|895898290|ref|WP_048999361.1|	37.6	221	229	646	6.10e-41	146
k141_33907_4	SARG|gi|896106549|ref|WP_049136608.1|	37.6	221	229	646	6.10e-41	146
k141_33907_4	SARG|gi|798937928|ref|WP_045908399.1|	37.6	221	229	646	6.10e-41	146
k141_33907_4	SARG|gi|654544841|ref|WP_028012549.1|	37.6	221	229	646	8.40e-41	146
k141_33907_4	SARG|gi|695748190|ref|WP_032674455.1|	37.6	221	229	646	8.40e-41	146
k141_33907_4	SARG|gi|544824889|ref|WP_021240890.1|	37.6	221	229	646	8.40e-41	146
k141_33907_4	SARG|gi|836589868|ref|WP_047747112.1|	37.6	221	229	646	8.40e-41	146
k141_33907_4	SARG|gi|779861244|ref|WP_045352062.1|	37.6	221	229	646	8.40e-41	146
k141_28205_3	NCBI|WP_063856927.1|1|1|vanZ-Pt|vanZ-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_protein_VanZ-Pt|AMR|glycopeptide	41.0	100	162	159	1.82e-15	68.6
k141_28205_3	SARG|gi|670466162|ref|WP_031414939.1|	37.3	67	162	206	8.87e-07	45.8
k141_28205_3	SARG|gi|515720450|ref|WP_017153050.1|	40.3	67	162	210	9.12e-07	45.8
k141_28205_3	SARG|gi|1028848471|ref|WP_064017434.1|	36.2	69	162	206	1.66e-06	45.1
k141_28205_3	SARG|AF155139.2.gene5.p01	38.8	67	162	206	7.91e-06	43.1
k141_30823_3	SARG|gi|654544841|ref|WP_028012549.1|	36.9	236	253	646	1.04e-37	138
k141_30823_3	SARG|gi|896106549|ref|WP_049136608.1|	36.9	236	253	646	1.42e-37	138
k141_30823_3	SARG|gi|983405167|ref|WP_060572706.1|	36.9	236	253	646	1.96e-37	137
k141_30823_3	SARG|gi|754493745|ref|WP_041910640.1|	36.9	236	253	646	2.68e-37	137
k141_30823_3	SARG|gi|782756348|ref|WP_045630015.1|	36.9	236	253	646	3.68e-37	137
k141_30823_3	SARG|gi|829942568|ref|WP_047368199.1|	36.4	236	253	646	5.05e-37	136
k141_30823_3	SARG|gi|779958642|ref|WP_045406003.1|	36.3	240	253	646	9.50e-37	135
k141_30823_3	SARG|gi|851913025|ref|WP_048215946.1|	34.3	236	253	648	9.59e-37	135
k141_30823_3	SARG|gi|489930965|ref|WP_003834285.1|	34.3	236	253	648	9.59e-37	135
k141_30823_3	SARG|gi|695731408|ref|WP_032657917.1|	36.4	236	253	646	1.30e-36	135
k141_34008_5	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	32.4	225	288	357	1.34e-21	92.0
k141_34008_5	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	32.4	225	288	357	1.34e-21	92.0
k141_34008_5	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	32.4	216	288	364	1.79e-20	89.0
k141_34008_5	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	32.4	216	288	364	1.79e-20	89.0
k141_34008_5	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.1	247	288	370	2.31e-19	85.9
k141_34008_5	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	31.8	211	288	359	5.37e-19	84.7
k141_34008_5	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.3	240	288	365	7.71e-19	84.3
k141_34008_5	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	33.6	220	288	364	1.04e-18	84.0
k141_34008_5	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	33.6	220	288	364	1.04e-18	84.0
k141_34008_5	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.1	225	288	354	4.56e-18	82.0
k141_8407_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.5	120	213	231	1.35e-12	63.5
k141_8407_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	31.7	120	213	232	9.23e-12	61.2
k141_8407_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.3	120	213	219	1.12e-08	52.4
k141_8407_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.1	161	213	228	2.25e-08	51.6
k141_8407_1	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	27.2	125	213	252	1.21e-07	49.7
k141_8407_1	CARD|gb|AAG06465.1|ARO:3005063|cprR	26.8	123	213	223	1.37e-07	49.3
k141_8407_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	31.5	92	213	229	2.23e-06	45.8
k141_28359_11	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	25.8	186	238	307	3.77e-17	77.8
k141_28359_11	SARG|gb|AAA26793|ARO:3003748|oleC	23.3	202	238	325	3.05e-10	58.2
k141_28359_11	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	23.3	202	238	325	3.05e-10	58.2
k141_42359_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.9	221	224	219	1.23e-40	137
k141_42359_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.9	219	224	228	1.86e-35	124
k141_42359_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.3	225	224	247	3.86e-32	116
k141_42359_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.2	227	224	231	1.12e-30	112
k141_42359_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.9	227	224	232	1.61e-30	111
k141_42359_2	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	30.7	218	224	233	1.46e-27	103
k141_42359_2	CARD|gb|AAG06465.1|ARO:3005063|cprR	31.5	222	224	223	2.30e-27	103
k141_42359_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	28.0	225	224	231	2.09e-26	100
k141_42359_2	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	28.4	229	224	232	1.38e-21	88.2
k141_42359_2	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.7	119	224	1197	2.92e-10	58.5
k141_8513_1	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	33.9	118	186	641	3.07e-12	63.2
k141_8513_4	SARG|AAN28721	56.8	74	402	108	3.43e-23	92.4
k141_45205_10	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	30.4	250	425	357	1.28e-28	114
k141_45205_10	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	30.4	250	425	357	1.28e-28	114
k141_45205_10	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.1	221	425	367	1.51e-25	105
k141_45205_10	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.1	221	425	368	1.53e-25	105
k141_45205_10	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	30.1	209	425	380	8.59e-23	98.2
k141_45205_10	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	30.1	209	425	380	8.59e-23	98.2
k141_45205_10	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	30.7	228	425	364	2.44e-22	96.7
k141_45205_10	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	29.2	253	425	364	2.44e-22	96.7
k141_45205_10	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	30.7	228	425	364	2.44e-22	96.7
k141_45205_10	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	29.2	253	425	364	2.44e-22	96.7
k141_45205_11	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.7	228	236	232	6.36e-69	210
k141_45205_11	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.7	228	236	232	6.36e-69	210
k141_45205_11	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	43.8	235	236	235	3.69e-66	203
k141_45205_11	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.9	228	236	231	6.53e-66	202
k141_45205_11	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.9	228	236	231	6.53e-66	202
k141_45205_11	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.9	230	236	231	7.47e-65	200
k141_45205_11	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.0	231	236	231	1.50e-64	199
k141_45205_11	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.0	231	236	231	3.01e-64	198
k141_45205_11	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	43.4	235	236	233	6.42e-64	197
k141_45205_11	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	43.2	234	236	239	1.55e-63	197
k141_24567_5	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	28.9	280	341	341	1.28e-33	125
k141_24567_6	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.9	217	224	219	1.22e-25	98.6
k141_24567_6	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.9	217	224	220	1.24e-25	98.6
k141_24567_6	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.9	217	224	219	2.39e-25	97.8
k141_24567_6	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.9	217	224	220	2.45e-25	97.8
k141_24567_6	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	31.5	222	224	225	1.47e-24	95.9
k141_24567_6	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.4	224	224	220	5.34e-23	91.7
k141_24567_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	27.9	219	224	228	1.72e-22	90.5
k141_24567_6	SARG|ZP_02848503	28.7	216	224	221	5.70e-22	89.0
k141_24567_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	26.2	225	224	232	7.08e-22	89.0
k141_24567_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	26.2	225	224	232	7.08e-22	89.0
k141_24567_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	49.2	256	259	255	9.50e-85	252
k141_24567_8	SARG|gi|1035686596|ref|WP_064530178.1|	36.3	256	259	648	2.96e-46	162
k141_24567_8	SARG|gi|979505419|ref|WP_059334195.1|	38.0	221	259	648	2.85e-45	159
k141_24567_8	SARG|ZP_04001960	38.0	221	259	648	2.85e-45	159
k141_24567_8	SARG|gi|754724054|ref|WP_042095806.1|	38.0	221	259	648	2.85e-45	159
k141_24567_8	SARG|gi|545164255|ref|WP_021518974.1|	38.0	221	259	648	2.85e-45	159
k141_24567_8	SARG|gi|486403059|ref|WP_001607116.1|	38.0	221	259	648	2.85e-45	159
k141_24567_8	SARG|gi|979422229|ref|WP_059319814.1|	38.0	221	259	648	2.85e-45	159
k141_24567_8	SARG|gi|1001782895|ref|WP_061321573.1|	38.0	221	259	648	2.85e-45	159
k141_24567_8	SARG|gi|754731641|ref|WP_042100724.1|	38.0	221	259	648	2.85e-45	159
k141_24567_9	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	58.5	53	63	578	1.26e-15	67.8
k141_24567_9	SARG|gi|664556405|ref|WP_031071225.1|	49.2	61	63	602	6.03e-15	65.9
k141_24567_9	SARG|gi|917155568|ref|WP_051762280.1|	54.7	53	63	620	1.54e-14	64.7
k141_24567_9	SARG|gi|917166849|ref|WP_051773561.1|	54.7	53	63	620	1.54e-14	64.7
k141_24567_9	SARG|gi|917172177|ref|WP_051778889.1|	54.7	53	63	620	2.88e-14	63.9
k141_24567_9	SARG|gi|919568551|ref|WP_052871170.1|	54.7	53	63	620	2.88e-14	63.9
k141_24567_9	SARG|gi|917229923|ref|WP_051836635.1|	54.7	53	63	620	2.88e-14	63.9
k141_24567_9	SARG|gi|921231571|ref|WP_053176464.1|	54.7	53	63	620	2.88e-14	63.9
k141_24567_9	SARG|gi|926351744|ref|WP_053683383.1|	54.7	53	63	648	2.88e-14	63.9
k141_24567_9	SARG|gi|496018010|ref|WP_008742581.1|	52.8	53	63	623	3.93e-14	63.5
k141_24684_6	SARG|YP_002333394	35.5	107	249	323	4.76e-10	57.8
k141_24684_6	SARG|AF310956.2.gene5.p01	34.6	107	249	323	1.58e-09	56.2
k141_24684_6	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	34.6	107	249	323	1.58e-09	56.2
k141_24684_6	SARG|gb|AAB05626.1|ARO:3002943|vanHB	33.6	107	249	323	1.58e-09	56.2
k141_24684_6	SARG|Q47748	33.6	107	249	323	2.86e-09	55.5
k141_24684_6	SARG|gi|498515089|ref|WP_010815296.1|	33.6	107	249	323	7.00e-09	54.3
k141_24684_6	SARG|AY082011.1.gene6.p01	31.5	108	249	323	7.00e-09	54.3
k141_24684_6	SARG|gi|985522333|ref|WP_060811962.1|	33.6	107	249	323	7.00e-09	54.3
k141_24684_6	SARG|gi|552942232|ref|WP_023043160.1|	31.5	108	249	323	1.27e-08	53.5
k141_24684_12	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	7.47e-89	283
k141_24684_12	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	1.05e-88	283
k141_24684_12	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	1.05e-88	283
k141_24684_12	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	1.05e-88	283
k141_24684_12	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	1.05e-88	283
k141_24684_12	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	1.05e-88	283
k141_24684_12	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	1.05e-88	283
k141_24684_12	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	42.3	366	478	655	1.47e-88	283
k141_24684_12	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	1.47e-88	283
k141_24684_12	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.8	392	478	655	2.06e-88	282
k141_24955_7	NCBI|AAD44693.1|1|1|mtrA_Ngon|mtrA_Ngon||1|EFFLUX|EFFLUX|efflux_transporter_MtrCDE_transcriptional_activator_MtrA|AMR|efflux	27.5	102	404	301	6.21e-08	52.8
